Novel compound for inhibiting protein kinases and pharmaceutical composition comprising same

A novel spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl compound addresses the inadequacies of existing protein tyrosine kinase inhibitors by providing selective and potent inhibition of protein kinases, effectively treating multiple cancer types with low toxicity.

WO2024242495A1PCT designated stage expired Publication Date: 2024-11-28MAGICBULLETTHERAPEUTICS CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007047
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-20
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current protein tyrosine kinase inhibitors are not selective enough and have limited anticancer effects, necessitating the development of more effective inhibitors to treat various protein kinase-related diseases, including cancer.

Method used

A novel spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl-based compound and its pharmaceutical compositions that selectively inhibit various protein kinases, including ABL1, ABL2/ARG, ACK1, and others, with low cytotoxicity and high antiproliferative effects on cancer cells.

Benefits of technology

The compound effectively inhibits multiple protein kinases, showing significant antiproliferative activity against various cancer types with minimal cytotoxicity, making it suitable for treating a range of cancer diseases such as prostate, lung, breast, and leukemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure WO-DOC-FIGURE-1011
    Figure WO-DOC-FIGURE-1011
  • Figure WO-DOC-FIGURE-1544
    Figure WO-DOC-FIGURE-1544
  • Figure WO-DOC-FIGURE-1788
    Figure WO-DOC-FIGURE-1788
Patent Text Reader

Abstract

The present invention relates to: a novel compound for inhibiting protein kinases; and a pharmaceutical composition comprising same. More specifically, the compound according to the present invention can effectively inhibit various protein kinases, and thus can be usefully used in the development of therapeutic agents for protein kinase-related diseases, particularly cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Novel compound for inhibiting protein kinase and pharmaceutical composition containing the same

[0001] The present invention relates to a novel compound for inhibiting protein kinase and a pharmaceutical composition comprising the same, and more particularly, to a novel compound selected from spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, a hydrate thereof or a stereoisomer thereof, a method for preparing the compound, and a pharmaceutical composition comprising the compound for preventing, alleviating or treating cancer.

[0002] Within cells, various cell signaling systems exist that regulate cell proliferation, growth, metastasis, and apoptosis, and each component is organically interconnected. When genetic or environmental factors disrupt these regulatory functions within cells, abnormal cell proliferation or disruption of the signaling system can occur, leading to the transformation of normal cells into tumor cells.

[0003] Protein tyrosine kinase (PTK) plays an important role in cell signaling related to cell growth, differentiation, and proliferation, and abnormal mutations or overexpression of specific protein tyrosine kinases disrupt the normal intracellular signaling system, causing various diseases such as cancer, inflammation, metabolic diseases, and brain diseases.

[0004] Protein tyrosine kinases are enzymes that catalyze the phosphorylation of hydroxyl groups on tyrosine residues in proteins. This catalytic process allows many growth factor receptor proteins to transmit signals from the outside to the inside of the cell. Normal interactions between growth factors and their receptors regulate cell growth, but mutations or overexpression of receptor proteins can trigger abnormal signaling, leading to the development of tumor cells.

[0005] However, there is still a need to develop more selective and effective protein tyrosine kinase inhibitors that exhibit superior anticancer effects than currently known protein tyrosine kinases.

[0006] The purpose of the present invention is to provide a novel compound for inhibiting protein kinase.

[0007] Another object of the present invention is to provide a pharmaceutical composition for treating or preventing a protein kinase-related disease, comprising the novel compound for inhibiting the protein kinase.

[0008] Another object of the present invention is to provide a health functional food for improving or preventing protein kinase-related diseases, which comprises the novel compound for inhibiting protein kinase.

[0009] The present invention provides a compound selected from the group consisting of a compound represented by the following chemical formula 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a precursor thereof, or a solvate thereof:

[0010] [Chemical Formula 1]

[0011]

[0012] In the above chemical formula 1, R 1 and R 2 may be the same or different, and are hydrogen or (C1~C4) alkyl, or R 1 and R 2 They combine with each other to form a tricyclic to pentacyclic ring structure;

[0013] X is selected from substituted or unsubstituted (C1~C4)alkyl, (C3~C6)cycloalkyl, (C4~C6)cycloalkenyl, phenyl, benzyl, or a 5- or 6-ring single or double heterocyclic compound, wherein said substitution is (C1~C4)alkyl, (C1~C4)alkoxy, (C3~C6)cycloalkyl, trifluoromethyl, trifluoromethyl(C1~C2)alkoxy, halo, hydroxy, imidazolyl, (C1~C2)alkylimidazolyl, (C1~C2)alkoxyphenyl, morpholino, cyano, oxo(=O), (C1~C2)alkoxy(C1~C2)alkyl(C1~C2)alkylamino, piperazinyl, (C1~C2)alkylpiperazinyl, At least one selected from the group consisting of ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino,

[0014] A is selected from morpholino or -NH-Y, wherein Y is hydrogen, or substituted or unsubstituted phenyl, benzyl, (C1~C4)alkyl, (C2~C3)alkenyl, (C3~C6)cycloalkyl, pyridinyl, pyrazolyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, or aztidine, wherein the substitution is selected from (C1~C2)alkyl, (C1~C4)alkoxy, piperazinyl, (C1~C2)alkylpiperazinyl, acetylpiperazinyl, morpholino, morpholine-4-carbonyl, (C1~C2)alkylpiperazin-1-carbonyl, oxetanyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl, imidazolyl, pyrrolidinyl, At least one selected from the group consisting of di(C1~C2)alkylaminopyrrolidinyl, piperidinyl, acetylpiperidinyl, di(C1~C2)alkylaminopiperidinyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl, halo, trifluoro(C1~C2)alkyl, trifluoro(C1~C2)alkoxy, di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, pyridinyl, furanyl, hydroxy, and tert-butoxy carbonyl (BOC); Z is CH or N; L is CH2 or NH; n1 or n2 can be an integer from 0 to 1.

[0015] The present invention provides a pharmaceutical composition for treating or preventing a protein kinase-related disease comprising the compound.

[0016] In addition, the present invention provides a health functional food for improving or preventing a protein kinase-related disease, comprising the compound.

[0017] The compound according to the present invention binds to ABL1, ABL2 / ARG, ACK1, ARAF, BLK, BMX / ETK, BRAF, BRK, BTK, C-KIT, C-SRC, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GLK / MAP4K3, HCK, HGK / MAP4K4, HIPK4, HPK1 / MAP4K1, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS2, LCK, LIMK1, LIMK2, LOK / STK10, LRRK2, LYN, LYN B, MEK5, MEKK2, MEKK3, MINK / MINK1, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, NEK4, P38A / MAPK14, P38B / MAPK11, PDGFRA, PDGFRB, PKAcg, PYK2, RAF1, RET, RIPK3, ROS / ROS1, RSK1, SIK1, SIK2, SIK3, SLK / STK2, SRMS, It has an excellent ability to inhibit the activity of various protein kinases, such as STK32B / YANK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TEC, TESK2, TIE2 / TEK, TNIK, TNK1, TRKA, TRKB, TRKC, TXK, TYK1 / LTK, TYK2, TYRO3 / SKY, YES / YES1, YSK4 / MAP3K19, ZAK / MLTK. Therefore, it can be used for the purpose of treating, preventing, and alleviating cancer diseases caused by abnormal cell growth related thereto.

[0018] The compound according to the present invention, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer diseases exhibit low cytotoxicity while selectively exhibiting high inhibitory activity and anti-proliferative effect on cancer cells, and thus can be usefully used for preventing or treating various cancer diseases such as gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenoma, uterine cancer, cervical cancer, head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer (including leukemia, multiple myeloma, and myelodysplastic syndrome), lymphoma (including Hodgkin's disease, Hodgkin's disease, and non-Hodgkin's lymphoma), psoriasis, or fibroadenoma.

[0019] Hereinafter, the present invention will be described in more detail.

[0020]

[0021] The present inventors have made diligent efforts to develop a more effective protein kinase inhibitor, and as a result, have synthesized a novel compound based on spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl, and have confirmed that the compound can effectively inhibit various protein kinases, thereby completing the present invention.

[0022]

[0023] Accordingly, the present invention provides a compound selected from the group consisting of a compound represented by the following chemical formula 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a precursor thereof, or a solvate thereof:

[0024] [Chemical Formula 1]

[0025]

[0026] In the above chemical formula 1, R 1 and R 2 may be the same or different, and are hydrogen or (C1~C4) alkyl, or R 1and R 2 They combine with each other to form a tricyclic to pentacyclic ring structure;

[0027] X is selected from substituted or unsubstituted (C1~C4)alkyl, (C3~C6)cycloalkyl, (C4~C6)cycloalkenyl, phenyl, benzyl, or a 5- or 6-ring single or double heterocyclic compound, wherein said substitution is (C1~C4)alkyl, (C1~C4)alkoxy, (C3~C6)cycloalkyl, trifluoromethyl, trifluoromethyl(C1~C2)alkoxy, halo, hydroxy, imidazolyl, (C1~C2)alkylimidazolyl, (C1~C2)alkoxyphenyl, morpholino, cyano, oxo(=O), (C1~C2)alkoxy(C1~C2)alkyl(C1~C2)alkylamino, piperazinyl, (C1~C2)alkylpiperazinyl, At least one selected from the group consisting of ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, and the 5-ring or 6-ring single or double heterocyclic compound is selected from the group consisting of thiophene, furan, pyrazole, oxazole, thiazole, pyridine, pyran, tetrahydropyran, oxazine, thiazine, pyrimidine, piperazine and benzothiazole,

[0028] A is selected from morpholino or -NH-Y, wherein Y is hydrogen, or substituted or unsubstituted phenyl, benzyl, (C1~C4)alkyl, (C2~C3)alkenyl, (C3~C6)cycloalkyl, pyridinyl, pyrazolyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, or aztidine, wherein the substitution is selected from (C1~C2)alkyl, (C1~C4)alkoxy, piperazinyl, (C1~C2)alkylpiperazinyl, acetylpiperazinyl, morpholino, morpholine-4-carbonyl, (C1~C2)alkylpiperazin-1-carbonyl, oxetanyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl, imidazolyl, pyrrolidinyl, At least one selected from the group consisting of di(C1~C2)alkylaminopyrrolidinyl, piperidinyl, acetylpiperidinyl, di(C1~C2)alkylaminopiperidinyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl, halo, trifluoro(C1~C2)alkyl, trifluoro(C1~C2)alkoxy, di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, pyridinyl, furanyl, hydroxy and tert-butoxy carbonyl (BOC), Z is CH or N, L is CH2 or NH, and n1 or n2 can be an integer from 0 to 1.

[0029]

[0030] Preferably, the compound may be a compound represented by chemical formula 1-1:

[0031] [Chemical Formula 1-1]

[0032]

[0033] In the above chemical formula 1-1,

[0034] X is selected from substituted or unsubstituted (C1~C4)alkyl, (C3~C6)cycloalkyl, (C4~C6)cycloalkenyl, phenyl, benzyl, or a 5- or 6-ring single or double heterocyclic compound, wherein said substitution is (C1~C4)alkyl, (C1~C4)alkoxy, (C3~C6)cycloalkyl, trifluoromethyl, trifluoromethyl(C1~C2)alkoxy, halo, hydroxy, imidazolyl, (C1~C2)alkylimidazolyl, (C1~C2)alkoxyphenyl, morpholino, cyano, oxo(=O), (C1~C2)alkoxy(C1~C2)alkyl(C1~C2)alkylamino, piperazinyl, (C1~C2)alkylpiperazinyl, At least one selected from the group consisting of ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, and the 5-ring or 6-ring single or double heterocyclic compound is selected from the group consisting of thiophene, furan, pyrazole, oxazole, thiazole, pyridine, pyran, tetrahydropyran, oxazine, thiazine, pyrimidine, piperazine and benzothiazole,

[0035] A is selected from morpholino or -NH-Y, wherein Y is hydrogen, or substituted or unsubstituted phenyl, benzyl, (C1~C4)alkyl, (C2~C3)alkenyl, (C3~C6)cycloalkyl, pyridinyl, pyrazolyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, or aztidine, wherein the substitution is selected from (C1~C2)alkyl, (C1~C4)alkoxy, piperazinyl, (C1~C2)alkylpiperazinyl, acetylpiperazinyl, morpholino, morpholine-4-carbonyl, (C1~C2)alkylpiperazin-1-carbonyl, oxetanyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl, imidazolyl, pyrrolidinyl, At least one selected from the group consisting of di(C1~C2)alkylaminopyrrolidinyl, piperidinyl, acetylpiperidinyl, di(C1~C2)alkylaminopiperidinyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl, halo, trifluoro(C1~C2)alkyl, trifluoro(C1~C2)alkoxy, di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, pyridinyl, furanyl, hydroxy and tert-butoxy carbonyl (BOC), wherein Z is CH or N, L is CH2 or NH, and n may be an integer from 0 to 1.

[0036]

[0037] More preferably, the compound may include a compound represented by Chemical Formula 1-2, 1-3, 1-4, 1-5 or 1-6:

[0038] [Chemical Formula 1-2]

[0039]

[0040] In the above chemical formula 1-2, R 3 Inland R 5are each the same or different and are selected from the group consisting of hydrogen, (C1~C2)alkyl, (C1~C2)alkoxy, trifluoromethyl, halo, hydroxy, (C1~C2)alkylimidazolyl, (C1~C2)alkoxyphenyl, morpholino, (C1~C2)alkoxy(C1~C2)alkyl(C1~C2)alkylamino, piperazinyl, (C1~C2)alkylpiperazinyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino,

[0041] A 1 is morpholino or -NH-Y 1 is selected from, and the above Y 1 is selected from hydrogen, (C3~C4)cycloalkyl, benzyl, 1H-pyrazolyl, di(C1~C2)alkyl1H-pyrazolyl, (oxetan-3-yl)-1H-pyrazolyl, trifluoro(C1~C2)alkyl-1H-pyrazolyl, pyridinyl(C1~C2)alkyl, hydroxy(C1~C2)alkyl, hydroxy(C2-C4)alkenyl, hydroxy(C3-C6)cycloalkyl, monopolyno(C3~C4)alkyl, furanyl(C1~C2)alkyl, tert-butoxy carbonyl (BOC) substituted aztidine, tetrahydropyranyl, benzothiazolyl, benzofuranyl or substituted or unsubstituted phenyl or pyridinyl, wherein said substitution is (C1~C2)alkyl, (C1~C2)alkoxy, halo, trifluoro(C1~C2)alkoxy, piperazinyl, (C1~C2)alkylpiperazinyl, acetylpiperazinyl, morpholino, morpholine-4-carbonyl, (C1~C2)alkylpiperazin-1-carbonyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl, imidazolyl, di(C1~C2)alkylaminopyrrolidinyl, piperidinyl, acetylpiperidinyl, di(C1~C2)alkylaminopiperidinyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino).

[0042]

[0043] [Chemical Formula 1-3]

[0044]

[0045] In the above chemical formula 1-3, X 1 is selected from (C3~C6)cycloalkyl, oxo(C3~C6)cycloalkyl, (C4~C6)cycloalkenyl, thiophene, (C1~C2)alkylthiophene, furan, thiazole, oxazole, benzothiazole, tetrahydropyran, trifluoro(C1~C3)alkyl; or pyridinyl substituted with a substituent selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy, trifluoromethyl, halo and hydroxy;

[0046] A 2 is morpholino or -NH-Y 2 is selected from, and the above Y 2 It may be at least one selected from the group consisting of hydrogen, benzyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, (C1~C2)alkylpyridinyl, pyridinyl(C1~C2)alkyl, hydroxy(C1~C2)alkyl, hydroxy(C2-C4)alkenyl, hydroxy(C3-C6)cycloalkyl, monopolyno(C3~C4)alkyl, furanyl(C1~C2)alkyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl-trifluoro(C1~C2)alkoxypyridinyl, and tert-butoxy carbonyl (BOC) substituted aztidine.

[0047]

[0048] [Chemical Formula 1-4]

[0049]

[0050] In the above chemical formula 1-4, X 2is selected from (C3~C6)cycloalkyl, (C3~C6)cycloalkyl(C1~C2)alkyl, benzyl, or substituted or unsubstituted phenyl, wherein the substitution may be one or more selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy, halo, trifluoro(C1~C2)alkyl, trifluoro(C1~C2)alkoxy and cyano,

[0051] A 3 is morpholino or -NH-Y 3 is selected from, and the above Y 3 may be at least one selected from hydrogen or (C1~C2)alkylpyridinyl.

[0052]

[0053] [Chemical Formula 1-5]

[0054]

[0055] In the above chemical formula 1-5, X 3 is selected from substituted or unsubstituted phenyl, wherein the substitution may be one or more selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy and halo,

[0056] A 4 is morpholino or -NH-Y 4 is selected from, and the above Y 4 may be at least one selected from hydrogen, benzyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, monopolyno(C3~C4)alkyl, furanyl(C1~C2)alkyl or pyridinyl(C1~C2)alkyl.

[0057]

[0058] [Chemical Formula 1-6]

[0059]

[0060] In the above chemical formula 1-6, X 4 is selected from substituted or unsubstituted phenyl, wherein the substitution is at least one selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy, halo and trifluoromethyl,

[0061] A 5 is morpholino or -NH-Y 5 is selected from, and the above Y 5 may be hydrogen, or one or more selected from (C1~C2)alkylpyridinyl.

[0062]

[0063] As an example, the compound is N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 1), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 2), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 3), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-fluoro-3-(trifluoromethyl)benzamide (Compound 4), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido]pyrimidine)-yl4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide (Compound 5), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide (Compound 6), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide (Compound 7), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide (Compound 8), N-(3-(2'-amino-7'-oxo-5'-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,4-Difluorobenzamide (Compound 9), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,4-difluorobenzamide (Compound 10), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide (Compound 11), N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (Compound 12), 3-bromo-N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)benzamide (Compound 13), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2,4-difluorobenzamide (Compound 14), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide (Compound 15), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxybenzamide (Compound 16), N-(3-(2'amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H-yl)-4-methylphenyl)-3-chloro-2-fluoro-5-(trifluoromethyl)benzamide (Compound 17), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-fluoro-5-(trifluoromethyl)benzamide (Compound 18),N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxy-5-(trifluoromethyl)benzamide (Compound 19), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4'-methoxy-5-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxyamide (Compound 20), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-6-(trifluoromethyl)picolinamide (Compound 21), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (Compound 22), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-hydroxy-5-(trifluoromethyl)benzamide (Compound 23), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 24), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-chloro-5-(trifluoromethyl)benzamide (Compound 25), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-chloro-5-(trifluoromethyl)benzamide (Compound 26), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide (Compound 27),N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide (Compound 28), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide (Compound 29), N-(3-(2'-(cycloamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide (Compound 30), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide (Compound 31), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 32), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 33), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 34), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 35),N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyl)(methyl)amino)-5-(trifluoromethyl)benzamide (Compound 36), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyl)(methylamino)-5-(trifluoromethyl)benzamide (Compound 37), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 38), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 39), N-(4-methyl-3-(2'-((4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 40), N-(4-methyl-3-(2'-((4-(4-methylpiperazine-1-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 41), N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 42), N-(4-methyl-3-(2'-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 43),N-(3-(2'-((4-(1H-imidazol-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 44), N-(4-methyl-3-(7'-oxo-2'-((4-(piperazin-1-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 45), (S)-N-(3-(2'-((4-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 46), N-(4-methyl-3-(7'-oxo-2'-((4-(piperidin-4-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 47), N-(4-methyl-3-(2'-((3-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 48), N-(3-(2'-((4-(1-acetylpiperidin-4-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 49), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (Compound 50), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 51), N-(4-methyl-3-(2'-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 52), N-(3-(2'-((2-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 53), N-(3-(2'-((2-methoxy-4-(morpholine-4-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 54), N-(3-(2'-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 55), N-(3-(2'-((3-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 56), N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 57), N-(3-(2'-((6-(4-ethylpiperazin-1-yl)-2-methoxypyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 58), N-(4-methyl-3-(7'-oxo-2'-(phenylamino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 59), N-(3-(2'-((4-(4-(dimethylaminopiperidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 60), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (Compound 61), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide (Compound 62), N-(3-(2'-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 63), N-(4-methyl-3-(7'-oxo-2'-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 64), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide (Compound 65), N-(3-(2'-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 66),N-(3-(2'-((3-methoxy-4-(piperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 67), N-(3-(2'-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 68), N-(3-(2'-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 69), N-(3-(2'-((2-hydroxy)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 70), 1-(4-Fluorophenyl)-3-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)urea (Compound 71), 4-chloro-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)benzamide (Compound 72), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)thiophene-2-carboxamide (Compound 73), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)furan-2-carboxamide (Compound 74), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclobutanecarboxamide (Compound 75), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-oxocyclobutane-1-carboxamide (Compound 76), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclohex-1-ene-1-carboxamide (Compound 77), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methylthiophene-2-carboxamide](Compound 78), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)isoxazole-5-carboxamide (Compound 79), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)benzo[d]thiazole-2-carboxamide (Compound 80), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4,4,4-trifluorobutanamide (Compound 81), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)thiazole-5-carboxamide (Compound 82), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclopentanecarboxamide (Compound 83), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)tetrahydro-2H-pyran-4-carboxamide (Compound 84),N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 85), N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 86), N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 87), N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 88), N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 89), N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 90), N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 91), N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 92), N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 93), N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 94), N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 95), N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 96), N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide (Compound 97), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 98), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 99), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 100), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 101), 2-(3,5-difluorophenyl)-N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide (Compound 102), N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 103), N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 104), N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 105), N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 106), N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 107), N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 108),N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide (Compound 109), 2-(3,5-difluorophenyl)-N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide (Compound 110), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 111), 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopropylurea (Compound 112), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclobutyl urea (Compound 113), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopentyl urea (Compound 114), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclopropylmethyl)urea (Compound 115), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclohexylmethyl)urea (Compound 116), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclohexylmethyl)urea (Compound 116).3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-benzylurea (Compound 117), 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-(trafluoromethoxy)phenyl)urea (Compound 118), 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-cyanophenyl)urea (Compound 119), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3,4-difluorophenyl)urea (Compound 120), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(2-methoxyphenyl)urea (Compound 121), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea (Compound 122), N-(5-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-6-methylpyridin-3-yl)-3-(trifluoromotyl)benzamide (Compound 123), N-Methyl-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamidide (Compound 124), 1-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(m-tolyl)urea (Compound 125), N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 126), (S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 127), N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 128), tert-butyl 3-((6'-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-2'-yl)amino)aztidine-1-carboxylate (Compound 129), N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 130), (S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 131), N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 132), tert-butyl 3-((6'-(2-methyl-5-(5-(trifluoromethyl)nicotinamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-2'-yl)amino)aztidine-1-carboxylate (Compound 133),and 3-(2'-amino-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Compound 134).

[0064]

[0065] The compound according to the present invention is ABL1, ABL2 / ARG, ACK1, ARAF, BLK, BMX / ETK, BRAF, BRK, BTK, C-KIT, C-SRC, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5. EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GLK / MAP4K3, HCK, HGK / MAP4K4, HIPK4, HPK1 / MAP4K1, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS2, LCK, LIMK1, LIMK2, LOK / STK10, LRRK2, LYN, LYN B, MEK5, MEKK2, MEKK3, MINK / MINK1, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, NEK4, P38A / MAPK14, P38B / MAPK11, PDGFRA, PDGFRB, PKAcg, PYK2, RAF1, RET, RIPK3, ROS / ROS1, RSK1, SIK1, SIK2, SIK3, SLK / STK2, SRMS, STK32B / YANK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TEC, TESK2, TIE2 / TEK, TNIK, TNK1, TRKA, TRKB, TRKC, TXK, It can inhibit one or more protein kinases selected from the group consisting of TYK1 / LTK, TYK2, TYRO3 / SKY, YES / YES1, YSK4 / MAP3K19, and ZAK / MLTK.

[0066]

[0067] As used herein, “stereoisomers” means two compounds having the same molecular formula but different arrangements of their atoms in space, and stereoisomers can be enantiomers, which are non-superimposable mirror images of each other, or diastereomers (e.g., cis / trans isomers and stereoconformational isomers) which are not mirror images of each other. These can include R and S configurations about each asymmetric center, Z and E double bond isomers, and Z and E stereoconformational isomers. Compositions containing single types of stereochemical isomers as well as enantiomers, diastereomers, and geometric (or stereoconformational) mixtures of the present compounds are within the scope of the present invention.

[0068] In this specification, “pharmaceutically acceptable salt” may be used in the form of either a pharmaceutically acceptable basic salt or acid salt. The basic salt may be used in the form of either an organic basic salt or an inorganic basic salt, and examples thereof include, but are not limited to, sodium salt, potassium salt, calcium salt, lithium salt, magnesium salt, cesium salt, and aminium salt, ammonium salt, triethylaminium salt, and pyridinium salt.

[0069] In addition, acid salts are useful as acid addition salts formed by free acids. Inorganic acids and organic acids can be used as free acids, and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfurous acid, phosphoric acid, etc. can be used, and organic acids such as citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, oxalic acid, malonic acid, glutaric acid, acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid, aspartic acid, etc. can be used. Preferably, hydrochloric acid can be used as an inorganic acid, and methanesulfonic acid can be used as an organic acid.

[0070] In addition, the composition according to the present invention may include not only pharmaceutically acceptable salts, but also all salts, hydrates and solvates that can be prepared by conventional methods.

[0071] The addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the compound in a water-miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile, adding an excess of an organic base or an aqueous solution of an inorganic base, and then precipitating or crystallizing. Alternatively, the addition salt can be obtained by evaporating the solvent or the excess base from the mixture and then drying it, or by suction filtration of the precipitated salt.

[0072] As used herein, "precursor" refers to a compound that, when administered to a subject or patient, can provide (directly or indirectly) a compound of the present invention. Examples of precursors include esterified or hydroxylated compounds whose ester or hydroxyl group is cleaved in vivo, e.g., in the intestine, to produce a compound according to Formula 1.

[0073] In this specification, "solvate" means an adduct of an inert solvent molecule onto a compound, which is formed by mutual attraction, and when the compound is treated with water, the solvate is a hydrate, for example, the solvate may be a monohydrate or dihydrate or an alkoxide.

[0074]

[0075] In addition, the present invention provides a pharmaceutical composition for treating or preventing a protein kinase-related disease comprising the compound.

[0076] In addition, the present invention provides a method for treating a protein kinase-related disease, comprising administering the compound to a subject suffering from a protein kinase-related disease.

[0077] The above protein kinases are ABL1, ABL2 / ARG, ACK1, ARAF, BLK, BMX / ETK, BRAF, BRK, BTK, C-KIT, C-SRC, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5. EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GLK / MAP4K3, HCK, HGK / MAP4K4, HIPK4, HPK1 / MAP4K1, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS2, LCK, LIMK1, LIMK2, LOK / STK10, LRRK2, LYN, LYN B, MEK5, MEKK2, MEKK3, MINK / MINK1, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, NEK4, P38A / MAPK14, P38B / MAPK11, PDGFRA, PDGFRB, PKAcg, PYK2, RAF1, RET, RIPK3, ROS / ROS1, RSK1, SIK1, SIK2, SIK3, SLK / STK2, SRMS, STK32B / YANK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TEC, TESK2, TIE2 / TEK, TNIK, TNK1, TRKA, TRKB, TRKC, TXK, It may be one or more selected from the group consisting of TYK1 / LTK, TYK2, TYRO3 / SKY, YES / YES1, YSK4 / MAP3K19, and ZAK / MLTK.

[0078] It is preferable that the compound has an inhibitory effect of 60% or more when treated with a single concentration of 1 μM of the compound against protein kinase.

[0079] The above protein kinase-related disease may be a cancer disease, and the cancer disease may be selected from the group consisting of prostate cancer, endometrial cancer, bladder cancer, stomach cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenoma, head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, urethral cancer, leukemia, multiple myeloma, blood cancer, lymphoma, and fibroadenoma, but is not limited thereto.

[0080] The above pharmaceutical composition may be administered in combination with one or more anticancer agents selected from the group consisting of cytotoxic anticancer agents, targeted anticancer agents, immunotherapy agents, and metabolic anticancer agents.

[0081] The above pharmaceutical composition may be provided in one or more dosage forms selected from the group consisting of gels, emulsions, injections, powders, granules, aerosols, pastes, transdermal absorbents, and patches according to a conventional method, but is not limited thereto.

[0082] In another specific embodiment of the present invention, the pharmaceutical composition may further comprise one or more additives selected from the group consisting of suitable carriers, excipients, disintegrants, sweeteners, coating agents, bulking agents, lubricants, glidants, flavoring agents, antioxidants, buffers, bacteriostatic agents, diluents, dispersants, surfactants, binders, and lubricants commonly used in the manufacture of pharmaceutical compositions.

[0083] Specifically, carriers, excipients, and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. These solid preparations may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like, into the composition. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents can be propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Base materials for suppositories include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.

[0084] The above pharmaceutical composition can be administered to a subject in a conventional manner via intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalation, topical, rectal, oral, intraocular or intradermal routes.

[0085] The preferred dosage of the compound may vary depending on the condition and weight of the subject, the type and severity of the disease, the drug form, the route and duration of administration, and may be appropriately selected by those skilled in the art. According to one embodiment of the present invention, although not limited thereto, the daily dosage may be 0.01 to 200 mg / kg, specifically 0.1 to 200 mg / kg, and more specifically 0.1 to 100 mg / kg. Administration may be administered once a day or divided into several doses, and the scope of the present invention is not limited thereby.

[0086] In the present invention, the 'subject' may be a mammal including a human, but is not limited to these examples.

[0087]

[0088] In addition, the present invention provides a health functional food for improving or preventing a protein kinase-related disease, comprising the compound.

[0089] The above protein kinases are ABL1, ABL2 / ARG, ACK1, ARAF, BLK, BMX / ETK, BRAF, BRK, BTK, C-KIT, C-SRC, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5. EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GLK / MAP4K3, HCK, HGK / MAP4K4, HIPK4, HPK1 / MAP4K1, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS2, LCK, LIMK1, LIMK2, LOK / STK10, LRRK2, LYN, LYN B, MEK5, MEKK2, MEKK3, MINK / MINK1, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, NEK4, P38A / MAPK14, P38B / MAPK11, PDGFRA, PDGFRB, PKAcg, PYK2, RAF1, RET, RIPK3, ROS / ROS1, RSK1, SIK1, SIK2, SIK3, SLK / STK2, SRMS, STK32B / YANK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TEC, TESK2, TIE2 / TEK, TNIK, TNK1, TRKA, TRKB, TRKC, TXK, It may be at least one selected from the group consisting of TYK1 / LTK, TYK2, TYRO3 / SKY, YES / YES1, YSK4 / MAP3K19, and ZAK / MLTK.

[0090] The above protein kinase-related disease may be a cancer disease, and the cancer disease may be selected from the group consisting of prostate cancer, endometrial cancer, bladder cancer, stomach cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenoma, head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, urethral cancer, leukemia, multiple myeloma, blood cancer, lymphoma, and fibroadenoma, but is not limited thereto.

[0091] In this specification, “health functional food” means a food manufactured and processed using raw materials or ingredients with functionality useful to the human body according to the Health Functional Food Act, and “functionality” means consumption for the purpose of obtaining a useful effect for health purposes, such as regulating nutrients for the structure and function of the human body or physiological action.

[0092] The above health functional food may contain conventional food additives, and its suitability as the above “food additive” shall be determined by the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additive Code approved by the Ministry of Food and Drug Safety, unless otherwise provided.

[0093] Items listed in the above "Food Additives Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high-molecular-weight pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, alkaline agents for noodles, preservative preparations, and tar color preparations.

[0094] The effective dosage of the active ingredient contained in the above health functional food can be used in accordance with the effective dosage of the above therapeutic agent, but in the case of long-term intake for the purpose of health and hygiene or health control, it may be below the above range. It is certain that the active ingredient can be used in an amount exceeding the above range because there is no problem in terms of safety.

[0095] There are no special restrictions on the types of the above health functional foods, and examples include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.

[0096] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0097]

[0098] <Example 1> Synthesis of a compound via synthetic route A - Compound 51

[0099] Compound 51 was synthesized through synthetic route A as shown in the following reaction scheme 1, and other compounds were synthesized in the same manner through synthetic route A. The synthetic method is described in detail based on compound 51.

[0100] [Reaction Formula 1]

[0101] [Correction pursuant to Rule 91, July 2024]

[0102]

[0103] 1-1) Step 1

[0104] 5-(Hydroxymethyl)pyrimidine-2,4-diol (8.0 g, 56.32 mmol) and phosphorus oxychloride (POCl3) (26.3 mL, 281.47 mmol) were added to toluene (180 mL), and nitrogen gas was injected for 5 minutes. The reaction vessel was placed in an ice-water bath at 0°C, N,N-diisopropylethylamine (29.4 mL, 168.88 mmol) was slowly added dropwise, and the mixture was refluxed and stirred at 120°C for 2 hours. After the reaction was completed, the mixed solution was cooled to room temperature, and water was added dropwise. The mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by MPLC (high-speed automatic separation purification system / ethyl acetate: hexane = 1: 30 (v / v)), and the obtained solution was concentrated under reduced pressure to obtain 9.3 g of the target compound as a white solid in 84% yield.

[0105] MS(m / z) : 195.95[M+1]+

[0106] 1 H NMR (400 MHz, CDCl3) δ 8.66 (s, 1H), 4.64 (s, 2H)

[0107]

[0108] 1-2) Step 2

[0109] 2,4-Dichloro-5-(chloromethyl)pyrimidine (27.8 g, 140.80 mmol) and 5-methyl-2-nitroaniline (27.8 g, 183.0 mmol) obtained in Step 1 were dissolved in acetone (300 mL), and then sodium iodide (27.4 g, 183.0 mmol) and potassium carbonate (38.9 g, 281.6 mmol) were added and stirred under reflux at 50°C for 3 days. After the reaction was completed, the mixed solution was cooled to room temperature, filtered using a Celite pad, and concentrated using a vacuum distillation apparatus. The concentrate was diluted with ethyl acetate and extracted with ethyl acetate and water. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: hexane = 1:20 (v / v)), and the solution was concentrated under reduced pressure to obtain 34.8 g of the target compound as a yellow solid in a yield of 78%.

[0110] MS(m / z) : 313.0[M+1]+

[0111] 1 H NMR (400 MHz, CDCl3) δ 8.50 (s, 1H), 7.61 (dd,J= 8.2, 2.2 Hz, 1H), 7.27 (d,J= 2.1 Hz, 1H), 7.23 (d,J= 8.2 Hz, 1H), 4.58 (s, 2H), 4.32 (s, 1H), 2.29 (s, 3H)

[0112]

[0113] 1-3) Step 3

[0114] N-((2,4-Dichloropyrimidin-5-yl)methyl)-2-methyl-5-nitroaniline (34.8 g, 111.1 mmol) obtained in the above step 2 was dissolved in anhydrous tetrahydrofuran (300 mL), and nitrogen gas was injected for 5 minutes to remove the gas contained in the mixed solution. After that, the reaction vessel was placed in a 0°C ice-water bath, 60% sodium hydride (5.7 g, 144.4 mmol) was added in portions, and the mixture was stirred at room temperature for 30 minutes. The mixed solution was placed in a 0°C ice-water bath, ethylmalonyl chloride (20.9 mL, 166.7 mmol) was added dropwise, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixed solution was placed in a 0°C ice-water bath, and the reaction was quenched using a saturated ammonium chloride solution. The remaining organic solvent was concentrated using a vacuum distillation apparatus, and the concentrate was diluted with water and extracted using dichloromethane. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: dichloromethane = 20:1 (v / v)), and the solution was concentrated under reduced pressure to obtain 43.1 g of the target compound as a white solid in 90% yield.

[0115] MS(m / z): 426.9[M+1]

[0116] 1 H NMR (400 MHz, CDCl3) δ 8.91 (s, 1H), 8.21 (dd,J= 8.5, 2.3 Hz, 1H), 7.93 (d,J= 2.3 Hz, 1H), 7.56 (d,J= 8.5 Hz, 1H), 5.32 (d,J= 15.4 Hz, 1H), 4.53 (d,J= 15.4 Hz, 1H), 4.14 (q,J= 7.1 Hz, 2H), 3.15 (dd,J= 37.9, 15.7 Hz, 2H), 2.37 (s, 3H), 1.23 (t,J= 7.2 Hz, 3H)

[0117]

[0118] 1-4) Step 4

[0119] 3-(((2,4-dichloroperimidin-5-yl)methyl)(2-methyl-5-nitrophenyl)amino)-3-oxopropanoate (39.2 g, 91.75 mmol) obtained in the above step 3 was dissolved in dimethyl sulfoxide (500 mL), and nitrogen gas was injected for 5 minutes. The reaction vessel was placed in an ice-water bath at 0°C, and cesium carbonate (44.8 g, 137.6 mmol) was added in portions, followed by stirring at room temperature for 2 hours. After completion of the reaction, the mixed solution was added dropwise to a 1 N hydrochloric acid aqueous solution (500 mL) at 0°C, and slowly stirred for 15 minutes. The yellow solid produced through stirring was filtered using a Celite pad, and the remaining organic solvent was washed with water. The obtained solid was dried to obtain 35.1 g of the target yellow solid compound in a yield of 97%.

[0120] MS(m / z): 391.1[M+1]

[0121]

[0122] 1-5) Step 5

[0123] Ethyl 2-chloro-6-(2-methyl-5-nitrophenyl)-7-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-8-carboxylate (35.1 g, 89.8 mmol) obtained in the above step 4 was dissolved in 1,4-dioxane (250 mL). 4N aqueous hydrochloric acid solution (222.5 mL, 890.1 mmol) dissolved in 1,4-dioxane was added, and the mixture was refluxed and stirred at 100°C for 16 hours. After the reaction was completed, the mixture was cooled to room temperature, the remaining solvent was removed under reduced pressure, and the remaining mixture was diluted with dichloromethane. The insoluble solid was filtered using a Celite pad, and the collected filtrate was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: dichloromethane = 3:7 (v / v)), and the solution was concentrated under reduced pressure to obtain 16.7 g of the target compound as a yellow solid in a yield of 58%.

[0124] MS(m / z): 319.05[M+1]

[0125] 1 H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.18 (dd,J= 8.4, 2.3 Hz, 1H), 8.12 (d,J= 2.2 Hz, 1H), 7.51 (d,J= 8.5 Hz, 1H), 4.97 (d,J= 16.1 Hz, 1H), 4.69 (d,J= 16.1 Hz, 1H), 4.02 (s, 2H), 2.29 (s, 3H)

[0126]

[0127] 1-6) Step 6

[0128] 2-Chloro-6-(2-methyl-5-nitrophenyl)-5,8-dihydropyrido[4,3-d]pyrimidin-7(6H)-one (10.0 g, 31.3 mmol) obtained in the above step 5 was dissolved in anhydrous dimethylformamide (150 mL), and nitrogen gas was injected for 5 minutes. The reaction vessel was placed in an ice-water bath at 0°C, and 1-bromo-2-chloroethane (4.6 mL, 37.6 mmol) was added, followed by the addition of cesium carbonate (22.4 g, 60.0 mmol) in portions. The mixed solution was stirred at room temperature for 16 hours. After completion of the reaction, the mixed solution was added dropwise to a 1 N hydrochloric acid aqueous solution (150 mL) at 0°C and slowly stirred for 15 minutes. The yellow solid produced through stirring was filtered using a Celite pad, and the remaining organic solvent was washed with water. The obtained solid was dried to obtain 9.23 g of the target yellow solid compound in 85% yield.

[0129] MS(m / z): 344.9[M+1]

[0130] 1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 8.21 - 8.10 (m, 2H), 7.50 (d,J= 8.1 Hz, 1H), 5.07 (d,J= 16.1 Hz, 1H), 4.77 (d,J= 16.1 Hz, 1H), 2.31 (s, 3H), 2.08 - 1.98 (m, 2H), 1.98 - 1.91 (m, 1H), 1.91 - 1.77 (m, 1H)

[0131]

[0132] 1-7) Step 7

[0133] 2'-Chloro-6'-(2-methyl-5-nitrophenyl)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (1.00 g, 0.77 mmol) obtained in the above step 6 was dissolved in tetrahydrofuran (10.0 mL), and methanol (5.0 mL) and water (3.0 mL) were added dropwise. Iron (0.81 g, 14.50 mmol) and ammonium chloride (0.77 g, 14.50 mmol) were added at room temperature, and the mixture was stirred under reflux at 80°C for 2 hours. After the reaction was completed, the mixed solution was cooled to room temperature and filtered using a Celite pad. The filtrate was neutralized by adding saturated aqueous sodium bicarbonate solution dropwise, and extracted with dichloromethane. The collected organic layer was dried over anhydrous sodium sulfate and concentrated to obtain 0.87 g of the target yellow solid compound in a yield of 95%.

[0134] MS(m / z): 315.1[M+1]

[0135] 1H NMR (400 MHz, MeOD) δ 8.46 (s, 1H), 7.05 (d,J= 8.2 Hz, 1H), 6.73 - 6.66 (m, 1H), 6.63 (d,J= 2.3 Hz, 1H), 4.99 (d,J= 16.9 Hz, 1H), 4.81 (d,J= 16.9 Hz, 1H), 2.04 (s, 3H), 1.89 (d,J= 4.5 Hz, 2H), 1.76 (dd,J= 4.9, 3.6 Hz, 2H)

[0136]

[0137] 1-8) Step 8

[0138] 6'-(5-Amino-2-methylphenyl)-2'-chloro-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (0.87 g, 2.77 mmol) obtained in the above step 7 was dissolved in dichloromethane (10.0 mL), and 3-(trifluoromethyl)benzoyl chloride (0.42 mL, 2.77 mmol) and potassium carbonate (0.76 g, 5.55 mmol) were added, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was diluted with dichloromethane, extracted with water, and the combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: hexane = 3:7 (v / v)), and the solution was concentrated under reduced pressure to obtain 0.87 g of the target compound as a yellow solid in a 64% yield.

[0139] MS(m / z): 487.1[M+1]

[0140] 1H NMR (400 MHz, MeOD) δ 8.48 (s, 1H), 8.25 (s, 1H), 8.19 (d,J= 7.8 Hz, 1H), 7.89 (d,J= 7.9 Hz, 1H), 7.79 (d,J= 2.1 Hz, 1H), 7.73 (t,J= 7.8 Hz, 1H), 7.59 (dd,J= 8.3, 2.1 Hz, 1H), 7.35 (d,J= 8.3 Hz, 1H), 5.08 (s, 1H), 4.89 (d,J= 16.8 Hz, 1H), 2.19 (s, 3H), 1.91 (t,J= 4.9 Hz, 2H), 1.80 (dt,J= 14.7, 10.5 Hz, 2H)

[0141]

[0142] 1-9) Step 9

[0143] N-(3-(2'-chloro-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (0.12 g, 0.24 mmol) obtained in step 8 above was dissolved in 2-butanol (10.0 mL), and then potassium carbonate (0.17 g, 1.23 mmol), 6-methylpyridin-3-amine (39 mg, 0.36 mmol), and tris(dibenzylideneacetone)dipalladium(0) (46 mg, 0.050 mmol) were added dropwise at room temperature. The reaction mixture was stirred at 100°C for 1 hour. After the reaction was completed, the mixed solution was cooled to room temperature, filtered using a Celite pad, and concentrated under reduced pressure. The obtained residue was purified by flash column chromatography (0-10% dichloromethane: methanol), and the solution was concentrated under reduced pressure to obtain 95.0 mg of the target compound (compound 51) as a brown solid in a 71% yield.

[0144] MS(m / z): 559.2[M+1]

[0145] 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H), 10.36 (s, 1H), 9.11 (s, 1H), 8.47 (s, 1H), 8.34 (d,J= 8.9 Hz, 1H), 8.31 (s, 1H), 8.27 (d,J= 7.6 Hz, 1H), 7.99 (d,J= 7.6 Hz, 1H), 7.84 - 7.75 (m, 2H), 7.71 (d,J= 7.4 Hz, 1H), 7.63 (dd,J= 8.3, 2.0 Hz, 1H), 7.34 (d,J= 8.4 Hz, 1H), 4.96 (d,J= 16.2 Hz, 1H), 4.78 (d,J= 16.1 Hz, 1H), 2.59 (s, 3H), 2.11 (s, 3H), 1.82 - 1.63 (m, 4H)

[0146]

[0147] 1-10) Synthesis of other compounds through synthetic route A

[0148] In step 9 above, the following compounds were also synthesized via synthetic route A using pyrazoleamine, phenylamine, or pyrimidinamine derivatives corresponding to each final synthetic compound instead of 6-methylpyridin-3-amine:

[0149] Compound 1 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], Compound 38 [N-(4-methyl-3-(2'-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], Compound 39 [N-(3-(2'-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 40 [N-(4-methyl-3-(2'-((4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 41 [N-(4-methyl-3-(2'-((4-(4-methylpiperazine-1-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 42 [N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 43 [N-(4-methyl-3-(2'-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 44 [N-(3-(2'-((4-(1H-imidazol-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide],Compound 45 [N-(4-methyl-3-(7'-oxo-2'-((4-(piperazin-1-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], Compound 46 [(S)-N-(3-(2'-((4-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], Compound 47 [N-(4-methyl-3-(7'-oxo-2'-((4-(piperidin-4-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 48 [N-(4-methyl-3-(2'-((3-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 49 [N-(3-(2'-((4-(1-acetylpiperidin-4-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 51 [N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 52 [N-(4-methyl-3-(2'-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 53 [N-(3-(2'-((2-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide]3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 54 [N-(3-(2'-((2-methoxy-4-(morpholine-4-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 55 [N-(3-(2'-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 56 [N-(3-(2'-((3-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 57 [N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 58 [N-(3-(2'-((6-(4-ethylpiperazin-1-yl)-2-methoxypyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 59 [N-(4-methyl-3-(7'-oxo-2'-(phenylamino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 60 [N-(3-(2'-((4-(4-(dimethylaminopiperidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide],Compound 63 [N-(3-(2'-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], Compound 64 [N-(4-methyl-3-(7'-oxo-2'-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], Compound 66 [N-(3-(2'-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 67 [N-(3-(2'-((3-methoxy-4-(piperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 68 [N-(3-(2'-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 69 [N-(3-(2'-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 71 [1-(4-fluorophenyl)-3-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)urea], compound 72 [4-chloro-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)benzamide], compound 73 [N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)thiophene-2-carboxamide], compound 74 [N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)furan-2-carboxamide], compound 103 [N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 104 [N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 105 [N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 106 [N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 107 [N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 108 [N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-Trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide], compound 109 [N-(3-(2'-(benzo[d]thiazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide], compound 110 [2-(3,5-difluorophenyl)-N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide], compound 111 [2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide],

[0150]

[0151] <Example 2> Synthesis of a compound via synthetic route B - Compound 8

[0152] Compound 8 was synthesized via synthetic route B as shown in the following reaction scheme 2, and other compounds were synthesized in the same manner via synthetic route B. The synthetic method is described in detail based on compound 8.

[0153] [Reaction Formula 2]

[0154] [Correction pursuant to Rule 91, July 2024]

[0155]

[0156] 2-1) Step 1

[0157] 2-Chloro-6-(2-methyl-5-nitrophenyl)-5,8-dihydropyrido[4,3-d]pyrimidin-7(6H)-one (0.2 g, 0.58 mmol) obtained in step 5 of Example 1 was dissolved in anhydrous dimethylacetamide (5.0 mL), cyclopropylamine (1.2 g, 0.38 mmol) and potassium carbonate (70 mg, 0.51 mmol) were added, and the mixture was stirred under reflux at 120°C for 16 hours. The mixture was concentrated under reduced pressure, and the obtained residue was dissolved in dichloromethane and washed with water. The combined organic layer was dried over sodium sulfate and concentrated, and the obtained residue was purified by MPLC (dichloromethane: ethyl acetate = 7:3 (v / v)) and concentrated to obtain 97 mg of the target compound in a yield of 46%.

[0158] MS(m / z): 366.15[M+1]

[0159] 1 H NMR (400 MHz, CDCl3) δ 8.19 - 8.05 (m, 3H), 7.47 (d,J= 9.2 Hz, 1H), 4.93 (d,J= 14.8 Hz, 1H), 4.61 (d,J= 14.8 Hz, 1H), 2.75 (dq,J= 6.6, 3.5 Hz, 1H), 2.30 (s, 3H), 1.87 - 1.68 (m, 4H), 0.82 (td,J= 6.7, 5.2 Hz, 2H), 0.59 - 0.48 (m, 2H)

[0160]

[0161] 2-2) Step 2

[0162] 2'-(Cyclopropylamino)-6'-(2-methyl-5-nitrophenyl)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (98 mg, 0.22 mmol) obtained in the above step 1 was dissolved in tetrahydrofuran (2.0 mL), and methanol (1.0 mL) and water (0.5 mL) were added dropwise. Iron (61 mg, 1.10 mmol) and ammonium chloride (59 mg, 1.10 mmol) were added at room temperature, and the mixture was stirred under reflux at 80°C for 2 hours. After the reaction was completed, the mixed solution was cooled to room temperature and filtered using a Celite pad. The filtrate was neutralized by adding saturated aqueous sodium bicarbonate solution dropwise, and extracted with dichloromethane. The collected organic layer was dried over anhydrous sodium sulfate and concentrated to obtain 73 mg of the target compound as a yellow solid in a yield of 99%.

[0163] MS(m / z): 336.0[M+1]

[0164] 1 H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H), 7.32 (s, 1H), 6.92 (d,J= 8.1 Hz, 1H), 6.47 (dd,J= 8.1, 2.1 Hz, 1H), 5.00 (s, 2H), 4.71 (d,J= 15.5 Hz, 1H), 4.53 (d,J= 15.4 Hz, 1H), 2.64 (ddd,J= 10.5, 7.1, 3.6 Hz, 1H), 1.91 (s, 3H), 1.65 - 1.47 (m, 4H), 0.68 - 0.58 (m, 2H), 0.48 - 0.37 (m, 2H)

[0165]

[0166] 2-3) Step 3

[0167] 6'-(5-amino-2-methylphenyl)-2'-(cyclopropylamino)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (50 mg, 0.159 mmol) obtained in the above step 2 was dissolved in dichloromethane (2.0 mL), and 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoro)benzoic acid (60 mg, 0.224 mmol), hexafluorophosphate azabenzotriazole tetramethyl uronium (111 mg, 0.298 mmol), and N,N-diisopropylethylamine (77.8 μL, 0.447 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The residue was concentrated under reduced pressure, and the obtained residue was dissolved in dichloromethane and washed with water. The combined organic layer was dried over sodium sulfate and concentrated, and the obtained residue was purified by HPLC (5:95 → 95:5 (v / v), for 40 min) and concentrated to obtain 21 mg of the target compound (Compound 8) in a yield of 23%.

[0168] MS(m / z): 588.20[M+1]

[0169] 1 H NMR (400 MHz, DMSO-d6) δ 10.65 (s, 1H), 9.50 (s, 1H), 8.57 (s, 1H), 8.42 (s, 2H), 8.15 (d,J= 24.9 Hz, 2H), 7.72 - 7.66 (m, 2H), 7.41 (s, 1H), 7.35 (d,J= 8.9 Hz, 1H), 4.80 (d,J= 15.3 Hz, 1H), 4.65 (d,J= 15.3 Hz, 1H), 2.34 (s, 3H), 2.10 (s, 3H), 1.77 - 1.48 (m, 4H), 0.65 (dd,J= 6.9, 2.3 Hz, 2H), 0.51 - 0.28 (m, 2H)

[0170]

[0171] 2-4) Synthesis of other compounds through synthetic route B

[0172] In step 3 above, the following compounds were also synthesized via synthetic route B using benzoic acid or pyridinecarboxylic acid derivatives corresponding to each final synthetic compound instead of 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoro)benzoic acid:

[0173] Compound 3 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], Compound 8 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide], Compound 10 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,4-difluorobenzamide], compound 11 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide], compound 12 [N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide], compound 13 [3-bromo-N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)benzamide], compound 27 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide], compound 28 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide], compound 30 [N-(3-(2'-(cycloamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide], compound 30 [N-(3-(2'-(cycloamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide]3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide], compound 32 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide], compound 35 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide], compound 36 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyl)(methyl)amino)-5-(trifluoromethyl)benzamide], compound 50 [N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide], compound 62 [N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide], compound 70 [N-(3-(2'-((2-hydroxy)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 85 [N-(3-(2'-(benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide],Compound 86 [N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], Compound 87 [N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], Compound 88 [N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 89 [N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide], compound 90 [N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 91 [N-(3-(2'-(benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 92 [N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide], compound 93 [N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide],Compound 94 [N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide], Compound 95 [N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide], Compound 96 [N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 97 [N-(3-(2'-(benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide], compound 98 [2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide], compound 99 [2-(3,5-difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide], compound 100 [2-(3,5-difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide], compound 101 [2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide], compound 102 [2-(3,5-Difluorophenyl)-N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide], compound 126 [N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 127 [(S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 128 [N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], compound 129 [tert-butyl 3-((6'-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-2'-yl)amino)aztidine-1-carboxylate], compound 130 [N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 131 [(S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 132 [N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide]3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 133 [tert-butyl 3-((6'-(2-methyl-5-(5-(trifluoromethyl)nicotinamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-2'-yl)amino)aztidine-1-carboxylate],

[0174]

[0175] <Example 3> Synthesis of a compound via synthetic route C - Compound 20

[0176] Compound 20 was synthesized via synthetic route C as shown in the following reaction scheme 3, and other compounds were synthesized in the same manner via synthetic route C. The synthetic method is described in detail based on compound 20.

[0177] [Reaction Formula 3]

[0178] [Correction pursuant to Rule 91, July 2024]

[0179]

[0180] 3-1) Step 1

[0181] 2'-Chloro-6'-(2-methyl-5-nitrophenyl)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (0.10 g, 0.29 mmol) obtained in step 6 of Example 1 was dissolved in dimethylformamide (1.0 mL), 4-methoxybenzylamine (0.06 mL, 0.43 mmol) and potassium carbonate were added, and the mixture was stirred under reflux at 90°C for 16 hours. After the reaction was completed, the mixed solution (0.08 g, 0.58 mmol) was diluted with water. The mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by MPLC (dichloromethane: ethyl acetate = 7:3 (v / v)), and the solution was concentrated under reduced pressure to obtain 45.0 mg of the target compound as a yellow solid in a 45% yield.

[0182] MS(m / z): 446.20[M+1]

[0183] 1 H NMR (400 MHz, CDCl3) δ 8.20 - 8.09 (m, 2H), 8.01 (s, 1H), 7.47 (d,J= 9.1 Hz, 1H), 7.27 (d,J= 6.9 Hz, 2H), 6.88 (d,J= 8.5 Hz, 2H), 4.90 (d,J= 14.8 Hz, 1H), 4.58 (d,J= 14.8 Hz, 1H), 4.52 (d,J= 5.7 Hz, 2H), 3.80 (s, 3H), 2.30 (s, 3H), 1.91 - 1.63 (m, 4H)

[0184]

[0185] 3-2) Step 2

[0186] 2'-((4-methoxybenzyl)amino)-6'-(2-methyl-5-nitrophenyl)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (5 g, 12.0 mmol) obtained in the above step 1 was dissolved in tetrahydrofuran (120 mL), and methanol (60 mL) and water (30 mL) were added dropwise. Iron (2.7 g, 48.3 mmol) and ammonium chloride (2.82 g, 52.7 mmol) were added at room temperature, and the mixture was stirred under reflux at 80°C for 2 hours. After the reaction was completed, the mixed solution was cooled to room temperature and filtered using a Celite pad. The filtrate was neutralized by adding a saturated aqueous sodium bicarbonate solution dropwise, and extracted with dichloromethane. The collected organic layer was dried over anhydrous sodium sulfate and concentrated to obtain 4.65 g of the target yellow solid compound in a yield of 99%.

[0187] MS(m / z): 416.20[M+1]

[0188] 1 H NMR (400 MHz, DMSO-d6) δ 8.11 (s, 1H), 7.22 (d,J= 8.5 Hz, 2H), 6.91 (d,J= 8.1 Hz, 1H), 6.85 (d,J= 8.6 Hz, 2H), 6.46 (dd,J= 8.1, 2.2 Hz, 1H), 6.41 (d,J= 2.1 Hz, 1H), 4.99 (s, 2H), 4.68 (d,J= 15.5 Hz, 1H), 4.50 (d,J= 15.5 Hz, 1H), 4.34 (s, 48H), 3.71 (s, 3H), 1.89 (s, 3H), 1.52 (s, 4H)

[0189]

[0190] 3-3) Step 3

[0191] 6'-(5-amino-2-methylphenyl)-2'-((4-methoxybenzyl)amino)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (40 mg, 0.10 mmol) obtained in the above step 2 was dissolved in dimethylformamide (1.2 mL), and then 3-methoxybenzene-5-(trifluoromethyl)benzoic acid (42.8 mg, 0.14 mmol), hexafluorophosphate azabenzotriazole tetramethyl uronium (73.2 mg, 0.19 mmol), and N,N-diisopropylethylamine (50.0 μL, 0.29 mmol) were added and stirred at room temperature for 3 hours. After the reaction was completed, the mixture was diluted with ethyl acetate, extracted with water, and the combined organic layer was dried over sodium sulfate and concentrated. The resulting residue was purified by MPLC (dichloromethane:ethyl acetate = 6:4 (v / v)), and the solution was concentrated under reduced pressure to obtain 40 mg of the target compound as a yellow solid in a 60% yield.

[0192] MS(m / z): 694.20[M+1]

[0193] 1 H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.47 (s, 1H), 8.18 (s, 1H), 8.14 (s, 2H), 7.86 - 7.77 (m, 2H), 7.74 - 7.59 (m, 3H), 7.32 (d,J= 8.4 Hz, 1H), 7.23 (d,J= 8.6 Hz, 2H), 7.14 - 7.05 (m, 2H), 6.86 (d,J= 8.6 Hz, 2H), 4.79 (d,J= 15.4 Hz, 1H), 4.61 (d,J= 15.4 Hz, 1H), 4.36 (d,J= 5.0 Hz, 2H), 3.83 (s, 3H), 3.71 (s, 3H), 2.08 (s, 3H), 1.66 - 1.40 (m, 4H)

[0194]

[0195] 3-4) Step 4

[0196] 4'-Methoxy-N-(3-(2'-((4-methoxybenzyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxyamide (73.3 mg, 0.106 mmol) obtained in the above step 3 was dissolved in a mixed solution of dichloromethane (2.0 mL) and trifluoroacetic acid (2.0 mL), and stirred under reflux at 65°C for 48 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by HPLC (5:95 → 95:5 (v / v), for 40 min) to obtain 8.5 mg of the target compound (compound 20) in a yield of 14%.

[0197] MS(m / z): 574.05[M+1]

[0198] 1 H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.48 (s, 1H), 8.25 - 8.07 (m, 3H), 7.83 (d,J= 8.3 Hz, 2H), 7.72 (s, 1H), 7.68 (d,J= 9.1 Hz, 1H), 7.33 (d,J= 8.3 Hz, 1H), 7.10 (d,J= 8.3 Hz, 2H), 6.67 (s, 2H), 4.79 (d,J= 15.5 Hz, 1H), 4.62 (d,J= 14.7 Hz, 1H), 3.83 (s, 3H), 2.09 (s, 3H), 1.67 - 1.44 (m, 4H)

[0199]

[0200] 3-5) Synthesis of other compounds through synthetic route C

[0201] In step 3 above, the following compounds were also synthesized via synthetic route C using benzoic acid or pyridinecarboxylic acid derivatives corresponding to each final synthetic compound instead of 3-methoxybenzene-5-(trifluoromethyl)benzoic acid:

[0202] Compound 2 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide], Compound 4 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-fluoro-3-(trifluoromethyl)benzamide], Compound 5 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido]pyrimidine)-yl4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide], compound 6 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide], compound 7 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide], compound 9 [N-(3-(2'-amino-7'-oxo-5'-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,4-difluorobenzamide], compound 14 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2,4-difluorobenzamide], compound 15 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide], compound 16 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxybenzamide], compound 17 [N-(3-(2'amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxybenzamide]3-d]pyrimidine]-6'(7'H-yl)-4-methylphenyl)-3-chloro-2-fluoro-5-(trifluoromethyl)benzamide], compound 18 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-fluoro-5-(trifluoromethyl)benzamide], compound 19 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxy-5-(trifluoromethyl)benzamide], compound 20 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4'-methoxy-5-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxyamide], compound 21 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-6-(trifluoromethyl)picolinamide], compound 22 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide], compound 23 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-hydroxy-5-(trifluoromethyl)benzamide], compound 24 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide], compound 25 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-chloro-5-(trifluoromethyl)benzamide], compound 26 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-chloro-5-(trifluoromethyl)benzamide], compound 26 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-chloro-5-(trifluoromethyl)benzamide], compound 29 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide], compound 31 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide], compound 33 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide], compound 34 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide], compound 37 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyll)(methylamino)-5-(trifluoromethyl)benzamide), compound 61 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide], compound 65 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide], compound 75 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclobutanecarboxamide], compound 76 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-oxocyclobutane-1-carboxamide], compound 77 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclohex-1-ene-1-carboxamide], compound 78 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methylthiophene-2-carboxamide], compound 79 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)isoxazole-5-carboxamide], compound 80 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)benzo[d]thiazole-2-carboxamide], compound 81 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4,4,4-trifluorobutanamide], compound 82 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)thiazole-5-carboxamide], compound 83 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclopentanecarboxamide], compound 84 [N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)tetrahydro-2H-pyran-4-carboxamide],

[0203]

[0204] <Example 4> Synthesis of a compound via synthetic route D - Compound 112

[0205] Compound 112 was synthesized through synthetic route D as shown in the following reaction scheme 4, and other compounds were synthesized in the same manner through synthetic route D. The synthetic method is described in detail based on compound 112.

[0206] [Reaction Formula 4]

[0207] [Correction pursuant to Rule 91, July 2024]

[0208]

[0209] 4-1) Step 1

[0210] 6'-(5-amino-2-methylphenyl)-2'-((4-methoxybenzyl)amino)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (35.0 mg, 0.08 mmol) obtained in step 2 of Example 3 was dissolved in tetrahydrofuran (1.5 mL), 3-(trifluoromethyl)phenylisocyanate (19.0 mg, 0.10 mmol) was added, and the mixture was stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed under reduced pressure, and the remaining mixture was diluted with acetonitrile. The insoluble solid was filtered using a Celite pad and washed with acetonitrile. The obtained solid was dried to obtain 12.6 mg of the target compound as a white solid in a 25% yield.

[0211] MS(m / z): 603.20[M+1]

[0212]

[0213] 4-2) Step 2

[0214] 1-(3-(2'-((4-methoxybenzyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea (9.0 mg, 15 μmol) obtained in the above step 1 was dissolved in a solution of trifluoroacetic acid (1.0 mL), and then anisole (3.0 μL, 30 μmol) was added and stirred under reflux at 75°C for 3 hours. After completion of the reaction, the mixture was slowly added dropwise to a saturated sodium bicarbonate aqueous solution at 0°C and stirred slowly for 15 minutes. The mixed solution was extracted with a dichloromethane:methanol (9:1) solvent, and the combined organic layer was dried over sodium sulfate. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by HPLC (5:95 → 95:5 (v / v), for 40 min) to obtain 1.5 mg of the target compound (compound 112) in a yield of 14%.

[0215] MS(m / z): 483.15[M+1]

[0216] 1 H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H), 8.84 (s, 1H), 8.12 (s, 1H), 8.05 (s, 1H), 7.62 - 7.44 (m,J= 6.6, 2.9, 1.2 Hz, 3H), 7.31 (d,J= 7.1 Hz, 1H), 7.28 - 7.16 (m, 2H), 6.63 (s, 2H), 4.80 (d,J= 15.0 Hz, 1H), 4.58 (d,J= 15.5 Hz, 1H), 2.08 (s, 3H), 1.66 - 1.45 (m, 4H)

[0217]

[0218] 4-3) Synthesis of other compounds through synthetic route D

[0219] The following compounds were synthesized via synthetic route D:

[0220] Compound 112 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopropylurea], Compound 113 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclobutylurea], Compound 114 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopentylurea], compound 115 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclopropylmethyl)urea], compound 116 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclohexylmethyl)urea], compound 117 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-benzylurea], compound 118 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-(trafluoromethoxy)phenyl)urea], compound 119 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-cyanophenyl)urea], compound 120 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3,4-difluorophenyl)urea], compound 121 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3,4-difluorophenyl)urea]3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(2-methoxyphenyl)urea], compound 122 [1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea], compound 125 [1-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(m-tolyl)urea],

[0221]

[0222] <Example 5> Synthesis of a compound via synthetic route E - Compound 123

[0223] Compound 123 was synthesized through synthetic route E as shown in the following reaction scheme 5, and the synthetic method was described.

[0224] [Reaction Formula 5]

[0225] [Correction pursuant to Rule 91, July 2024]

[0226]

[0227] 5-1) Step 1

[0228] 2,4-Dichloro-5-(chloromethyl)pyrimidine (6.95 g, 35.20 mmol) and 2-methyl-5-nitro-3-pyridinamine (7.01 g, 45.76 mmol) obtained in Step 1 of Example 1 were dissolved in acetone (70 mL), and then sodium iodide (6.86 g, 45.76 mmol) and potassium carbonate (9.73 g, 70.40 mmol) were added and stirred under reflux at 50°C for 2 hours. After the reaction was completed, the mixed solution was cooled to room temperature, filtered using a Celite pad, and concentrated using a reduced pressure distillation apparatus. The concentrate was diluted with ethyl acetate, and extracted with ethyl acetate and water. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (dichloromethane: ethyl acetate = 7:3 (v / v)), and the solution was concentrated under reduced pressure to obtain 3.4 g of the target compound as a yellow solid in a yield of 31%.

[0229] MS(m / z): 313.9[M+1]

[0230] 1 H NMR (400 MHz, CDCl3) δ 8.79 (d,J= 2.2 Hz, 1H), 8.52 (s, 1H), 7.45 (d,J= 2.2 Hz, 1H), 4.57 (d,J= 5.9 Hz, 2H), 4.40 (t,J= 5.6 Hz, 1H), 2.57 (s, 3H)

[0231]

[0232] 5-2) Step 2

[0233] N-((2,4-dichloropyrimidin-5-yl)methyl)-2-methyl-5-nitropyridin-3-amine (3.80 g, 12.10 mmol) obtained in Step 1 was dissolved in anhydrous tetrahydrofuran (100 mL), and nitrogen gas was injected for 5 minutes to remove the gas contained in the mixed solution. After that, the reaction vessel was placed in a 0°C ice-water bath, 60% sodium hydride (0.51 g, 12.70 mmol) was added in portions, and the mixture was stirred at room temperature for 1 hour. The mixed solution was placed in a 0°C ice-water bath, ethylmalonyl chloride (2.28 mL, 18.15 mmol) was added dropwise, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixed solution was placed in a 0°C ice-water bath, and the reaction was quenched using a saturated ammonium chloride solution. The remaining organic solvent was concentrated using a vacuum distillation apparatus, the concentrate was diluted with water, and extracted using dichloromethane. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: hexane = 3:7 (v / v)), and the solution was concentrated under reduced pressure to obtain 3.5 g of the target compound as a white solid in 68% yield.

[0234] MS(m / z) : 428.00 [M+1]

[0235] 1 H NMR (400 MHz, CDCl3) δ 9.40 (d,J= 2.4 Hz, 1H), 8.95 (s, 1H), 8.20 (d,J= 2.4 Hz, 1H), 5.36 (d,J= 15.3 Hz, 1H), 4.52 (d,J= 15.3 Hz, 1H), 4.13 (qd,J= 7.1, 2.0 Hz, 2H), 3.25 (d,J= 15.7 Hz, 1H), 3.09 (d,J= 15.7 Hz, 1H), 2.64 (s, 3H), 1.23 (t,J= 7.2 Hz, 3H)

[0236]

[0237] 5-3) Step 3

[0238] Ethyl 3-(((2,4-dichloropyrimidin-5-yl)methyl)(2-methyl-5-nitropyridin-3-yl)amino)-3-oxopropanate (1.66 g, 3.88 mmol) obtained in the above step 2 was dissolved in dimethyl sulfoxide (30 mL), and nitrogen gas was injected for 5 minutes. The reaction vessel was placed in an ice-water bath at 0°C, and cesium carbonate (1.51 g, 4.65 mmol) was added in portions, and the mixture was stirred at 30°C for 2 hours. After completion of the reaction, the mixed solution was added dropwise to a 1 N hydrochloric acid aqueous solution (200 mL) at 0°C, and the mixture was slowly stirred for 15 minutes. The mixed solution was extracted using dichloromethane, and the combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (dichloromethane: ethyl acetate = 7:3 (v / v)), and the solution was concentrated under reduced pressure to obtain 0.45 g of the target compound as a yellow solid in a 30% yield.

[0239] MS(m / z): 392.00[M+1]

[0240]

[0241] 5-4) Step 4

[0242] Ethyl 2-chloro-6-(2-methyl-5-nitropyridin-3-yl)-7-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-8-carboxylate (0.34 g, 0.87 mmol) obtained in the above step 3 was dissolved in 1,4-dioxane (10 mL). A 4N aqueous solution of hydrochloric acid dissolved in 1,4-dioxane (0.56 mL, 8.68 mmol) was added, and the mixture was refluxed at 100°C for 2 hours. After the reaction was completed, the mixture was cooled to room temperature, the remaining solvent was removed under reduced pressure, and the remaining mixture was diluted with dichloromethane. The insoluble solid was filtered using a Celite pad, and the collected filtrate was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: dichloromethane = 6:4 (v / v)), and the solution was concentrated under reduced pressure to obtain 0.15 g of the target compound as a yellow solid in a 53% yield.

[0243] MS(m / z): 319.95 [M+1]

[0244] 1 H NMR (400 MHz, CDCl3) δ 9.37 (d,J= 2.4 Hz, 1H), 8.55 (s, 1H), 8.36 (d,J= 2.4 Hz, 1H), 4.95 (d,J= 15.9 Hz, 1H), 4.75 (d,J= 15.8 Hz, 1H), 4.04 (s, 2H), 2.55 (s, 3H)

[0245]

[0246] 5-5) Step 5

[0247] 2-Chloro-6-(2-methyl-5-nitropyridin-3-yl)-5,8-dihydropyrido[4,3-d]pyrimidin-7(6H)-one (0.12 g, 0.37 mmol) obtained in the above step 4 was dissolved in anhydrous dimethylformamide (3.0 mL), and nitrogen gas was injected for 5 minutes. After that, (2-bromoethyl)diphenylsulfonium trifluoromethanesulfonate (0.25 g, 0.56 mmol) was added, and the mixture was stirred at room temperature for 5 minutes. Triethylamine (0.16 mL, 0.56 mmol) was slowly added to the mixture, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction was quenched using a saturated ammonium chloride solution, and extracted using dichloromethane. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: dichloromethane = 3:7 (v / v)), and the solution was concentrated under reduced pressure to obtain 87.0 mg of the target compound as a yellow solid in a 67% yield.

[0248] MS(m / z): 346.05[M+1]

[0249] 1 H NMR (400 MHz, CDCl3) δ 9.36 (d,J= 2.4 Hz, 1H), 8.39 (d,J= 2.5 Hz, 2H), 5.06 (d,J= 15.8 Hz, 1H), 4.82 (d,J= 15.8 Hz, 1H), 2.57 (s, 3H), 2.10 - 1.85 (m, 4H)

[0250]

[0251] 5-6) Step 6

[0252] 2'-Chloro-6'-(2-methyl-5-nitropididin-3-yl)-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (0.08 g, 0.23 mmol) obtained in the above step 5 was dissolved in tetrahydrofuran (4.0 mL), and methanol (2.0 mL) and water (1.0 mL) were added. Iron (0.06 g, 1.16 mmol) and ammonium chloride (0.06 g, 1.16 mmol) were added at room temperature, and the mixture was stirred under reflux at 80°C for 2 hours. After the reaction was completed, the mixed solution was cooled to room temperature and filtered using a Celite pad. The filtrate was diluted with water and extracted with dichloromethane. The collected organic layer was dried over anhydrous sodium sulfate and concentrated to obtain 62.6 mg of the target compound as a pale yellow solid in a yield of 91%.

[0253] MS(m / z): 316.10.00[M+1]

[0254] NMR: 1 H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 8.06 (d,J= 2.6 Hz, 1H), 6.89 (d,J= 2.6 Hz, 1H), 4.90 (d,J= 16.5 Hz, 1H), 4.79 (d,J= 16.4 Hz, 1H), 3.72 (s, 2H), 2.33 (s, 3H), 2.08 - 2.00 (m, 2H), 1.92 - 1.83 (m, 2H)

[0255]

[0256] 5-7) Step 7

[0257] 6'-(5-Amino-2-methylpyridin-3-yl)-2'-chloro-5',6'-dihydro-7'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-7'-one (0.07 g, 0.22 mmol) obtained in the above step 6 was dissolved in dichloromethane (5.0 mL), and 3-(trifluoromethyl)benzoyl chloride (0.06 mL, 0.40 mmol) and potassium carbonate (0.06 g, 0.44 mmol) were added, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction was quenched with water and extracted with dichloromethane. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: dichloromethane = 4:6 (v / v)), and the solution was concentrated under reduced pressure to obtain 62.6 g of the target compound as a yellow solid in a yield of 58%.

[0258] MS(m / z): 488.00[M+1]

[0259] 1 H NMR (400 MHz, CDCl3) δ 8.83 (s, 1H), 8.42 (d,J= 2.3 Hz, 1H), 8.37 (s, 1H), 8.29 (d,J= 2.4 Hz, 1H), 8.17 (s, 1H), 8.13 (d,J= 7.8 Hz, 1H), 7.86 (d,J= 7.8 Hz, 1H), 7.67 (t,J= 7.8 Hz, 1H), 5.05 (d,J= 16.3 Hz, 1H), 4.80 (d,J= 16.6 Hz, 1H), 2.19 (s, 3H), 2.14 - 1.88 (m, 4H)

[0260]

[0261] 5-8) Step 8

[0262] N-(5-(2'-chloro-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide (0.06 g, 0.12 mmol) obtained in step 7 above was dissolved in dimethyl sulfoxide (3.0 mL), and 4-methoxybenzylamine (0.16 mL, 1.23 mmol) was added dropwise at room temperature. The reaction mixture was stirred at 90°C for 2 hours. After the reaction was completed, the mixed solution was diluted with water and extracted with ethyl acetate, and the combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (dichloromethane: methanol = 95:5 (v / v)), and the solution was concentrated under reduced pressure to obtain 65.8 mg of the target yellow solid compound (compound 123) in 91% yield.

[0263] MS(m / z): 589.20[M+1]

[0264] 1 H NMR (400 MHz, DMSO-d6) δ 8.78 (d,J= 2.3 Hz, 1H), 8.33 (s, 1H), 8.29 (d,J= 7.9 Hz, 1H), 8.17 (d,J= 2.3 Hz, 1H), 8.14 (s, 1H), 8.01 (d,J= 7.8 Hz, 1H), 7.82 (t,J= 7.8 Hz, 1H), 6.90 - 6.84 (m, 4H), 4.85 (d,J= 15.1 Hz, 1H), 4.66 (d,J= 15.2 Hz, 1H), 3.73 (s, 3H), 3.66 (s, 2H), 2.28 (s, 3H), 1.68 - 1.45 (m, 4H)

[0265]

[0266] 5-9) Step 9

[0267] N-(5-(2'-((4-methoxybenzyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide (0.65 mg, 0.11 mmol) obtained in the above step 8 was dissolved in a solution of trifluoroacetic acid (3.0 mL), and then anisole (23.0 μL, 0.22 mmol) was added and stirred under reflux at 75°C for 3 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the obtained residue was purified by MPLC (dichloromethane: methanol = 95:5 (v / v)). The solution was concentrated under reduced pressure to obtain 32.0 mg of the target compound as a pale yellow solid (Compound 123, N-(5-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-6-methylpyridin-3-yl)-3-(trifluoromotel)benzamide) in a yield of 62%.

[0268] MS(m / z): 469.10[M+1]

[0269] NMR: 1 H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 8.78 (d,J= 2.3 Hz, 1H), 8.34 (s, 1H), 8.29 (d,J= 7.9 Hz, 1H), 8.20 (d,J= 2.3 Hz, 1H), 8.13 (s, 1H), 8.01 (d,J= 7.8 Hz, 1H), 7.82 (t,J= 7.8 Hz, 1H), 6.68 (s, 2H), 4.85 (d,J= 15.1 Hz, 1H), 4.67 (d,J= 15.2 Hz, 1H), 2.30 (s, 3H), 1.68 - 1.50 (m, 4H)

[0270]

[0271] <Example 6> Synthesis of a compound via synthetic route F - Compound 124

[0272] Compound 124 was synthesized via synthetic route F as shown in the following reaction scheme 6. The synthetic method was described in detail based on compound 124.

[0273] [Reaction Formula 6]

[0274] [Correction pursuant to Rule 91, July 2024]

[0275]

[0276] 6-1) Step 1

[0277] N-(3-(2'-chloro-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (250 mg, 0.51 mmol), methyl iodide (0.16 mL, 2.57 mmol), and potassium carbonate (213 mg, 1.54 mmol) were added to N N-dimethylformamide (3 mL), and the mixture was stirred under reflux at 120°C for 12 hours. After the reaction was completed, the mixed solution was cooled to room temperature, and water was added dropwise. The obtained residue was purified by flash column chromatography (0-5% dichloromethane: methanol), and the solution was concentrated under reduced pressure to obtain 120 mg of the solid target compound in a 47% yield.

[0278] MS(m / z): 501[M+1]

[0279]

[0280] 6-2) Step 2

[0281] N-(3-(2'-chloro-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methylphenyl)-N-methyl-3-(trifluoromethyl)benzamide (0.12 g, 0.24 mmol) obtained in Step 1 above was dissolved in 2-butanol (10.0 mL), and then potassium carbonate (0.17 g, 1.23 mmol), 6-methylpyridin-3-amine (39 mg, 0.36 mmol), and tris(dibenzylideneacetone)dipalladium(0) (46 mg, 0.050 mmol) were added dropwise at room temperature. The reaction mixture was stirred at 100°C for 1 hour. After the reaction was completed, the mixed solution was cooled to room temperature, filtered using a celite pad, and concentrated under reduced pressure. The obtained residue was purified by flash column chromatography (0-5% dichloromethane: methanol), and the solution was concentrated under reduced pressure to obtain 104 mg of the target compound as a brown solid (Compound 124, N-methyl-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide) in a yield of 76%.

[0282] MS(m / z): 573[M+1]

[0283]

[0284] <Example 7> Synthesis of a compound via synthetic route G - Compound 134

[0285] Compound 134 was synthesized through synthetic route G as shown in the following reaction scheme 7, and the synthetic method was described.

[0286] [Reaction Formula 7]

[0287] [Correction pursuant to Rule 91, July 2024]

[0288]

[0289] 7-1) Step 1

[0290] 2,4-Dichloro-5-(chloromethyl)pyrimidine (27.8 g, 140.80 mmol) and methyl 3-amino-4-methylbenzoate (30.24 g, 183.04 mmol) obtained in Step 1 of Example 1 were dissolved in acetone (300 mL), and then sodium iodide (27.44 g, 183.04 mmol) and potassium carbonate (38.92 g, 281.60 mmol) were added and stirred under reflux at 50°C for 2 hours. After the reaction was completed, the mixed solution was cooled to room temperature, filtered using a Celite pad, and concentrated using a reduced pressure distillation apparatus. The concentrate was diluted with ethyl acetate and extracted with ethyl acetate and water. The combined organic layer was dried over sodium sulfate and concentrated. The solution was concentrated under reduced pressure to obtain 36.3 g of the target compound as a yellow oil in a yield of 79.0%, which was used in the next reaction without separation.

[0291] MS(m / z): 326 [M+1]

[0292]

[0293] 7-2) Step 2

[0294] Methyl 3-(((2,4-dichloropyrimidin-5-yl)methyl)amino)-4-methylbenzoate (36.3 g, 111.13 mmol) obtained in the above step 1 was dissolved in anhydrous tetrahydrofuran (300 mL), and nitrogen gas was injected for 5 minutes to remove the gas contained in the mixed solution. After that, the reaction vessel was placed in an ice-water bath at 0°C, 60% sodium hydride (5.78 g, 144.47 mmol) was added in portions, and the mixture was stirred at room temperature for 1 hour. The reaction vessel was placed in an ice-water bath at 0°C, ethylmalonyl chloride (20.92 mL, 166.69 mmol) was added dropwise, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixed solution was placed in an ice-water bath at 0°C, and the reaction was quenched using a saturated ammonium chloride solution. The remaining organic solvent was concentrated using a vacuum distillation apparatus, and the concentrate was diluted with water and extracted using dichloromethane. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (ethyl acetate: hexane = 3:7 (v / v)), and the solution was concentrated under reduced pressure to obtain 20.2 g of the target compound as a yellow oil in a yield of 41.2%.

[0295] MS(m / z): 440 [M+1]

[0296]

[0297] 7-3) Step 3

[0298] Methyl 3-(N-((2,4-dichloropyrimidin-5-yl)methyl)-3-ethoxy-3-oxopropanamido)-4-methylbenzoate (0.3 g, 0.68 mmol) obtained in the above step 2 was dissolved in tetrahydrofuran (6.0 mL), and nitrogen gas was injected for 5 minutes. The reaction vessel was placed in an ice-water bath at 0°C, and sodium hydride 60% (0.04 g, 1.02 mmol) was added in portions, and the mixture was stirred at 30°C for 12 hours. After completion of the reaction, water was added to terminate the reaction, and extraction was performed using a solution (dichloromethane: methanol = 9:1). The collected organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (hexane: ethyl acetate = 4:6 (v / v)), and the solution was concentrated under reduced pressure to obtain 0.25 g of the target compound as a yellow solid in 91% yield.

[0299] MS(m / z): 404 [M+1]

[0300]

[0301] 7-4) Step 4

[0302] Ethyl 2-chloro-6-(5-(methoxycarbonyl)-2-methylphenyl)-7-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-8-carboxylate (0.3 g, 0.74 mmol) obtained in the above step 3 was dissolved in 1,4-dioxane (15 mL). 4N aqueous hydrochloric acid solution (0.3 mL, 7.4 mmol) dissolved in 1,4-dioxane was added, and the mixture was refluxed and stirred at 80°C for 1 hour. After the reaction was completed, the mixed solution was cooled to room temperature, the remaining solvent was removed under reduced pressure, and the remaining mixture was diluted with dichloromethane. The insoluble solid was filtered using a Celite pad, and the collected filtrate was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (hexane: ethyl acetate = 4:6 (v / v)), and the solution was concentrated under reduced pressure to obtain 0.1 g of the target yellow solid compound in a yield of 63%.

[0303] MS(m / z): 331 [M+1]

[0304]

[0305] 7-5) Step 5

[0306] Methyl 3-(2-chloro-7-oxo-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-4methylbenzoate (0.03 g, 0.093 mmol) obtained in the above step 4 was dissolved in anhydrous dimethylformamide (1.0 mL), and nitrogen gas was injected for 5 minutes. Then, (2-bromoethyl)diphenylsulfonium trifluoromethanesulfonate (0.06 g, 0.14 mmol) was added, and the mixture was stirred at room temperature for 5 minutes. Triethylamine (0.04 mL, 0.28 mol) was slowly added to the mixed solution, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction was quenched using a saturated ammonium chloride solution, and extracted using dichloromethane. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (hexane: ethyl acetate = 4:6 (v / v)), and the solution was concentrated under reduced pressure to obtain 28.3 mg of the target compound as a pale yellow solid in 85% yield.

[0307] MS(m / z): 358 [M+1]

[0308]

[0309] 7-6) Step 6

[0310] Methyl 3-(2'-chloro-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methylbenzoate (0.03 g, 0.014 mmol) obtained in the above step 5 was dissolved in tetrahydrofuran (0.5 mL) and water (0.5 mL) was added. Lithium hydroxide (0.06 g, 1.16 mmol) and ammonium chloride (18.0 mg, 0.42 mmol) were added at room temperature and the mixture was refluxed and stirred at 30°C for 2 hours. After the reaction was completed, 1 N hydrochloric acid aqueous solution was added dropwise to the mixture solution, adjusted to pH 2-3, diluted with water, and extracted with dichloromethane. The combined organic layer was dried over anhydrous sodium sulfate, concentrated, and proceeded to the next reaction without purification. 17.0 mg of the target compound as a pale yellow solid was obtained in a yield of 60%.

[0311] MS(m / z): 344 [M+1]

[0312]

[0313] 7-7) Step 7

[0314] 3-(2'-Chloro-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (17.0 mg, 0.05 mol) obtained in the above step 6 was dissolved in dimethylformamide (1 mL), and HATU (28.0 mg, 0.074 mmol), N,N-diisopropylethylamine (0.03 mL, 0.15 mmol), and 3-(trifluoromethyl)aniline (0.01 mL, 0.074 mmol) were added, and the mixture was stirred at 60°C for 3 hours. After the reaction was completed, the reaction was quenched with water and extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (hexane: ethyl acetate = 5:5 (v / v)), and the solution was concentrated under reduced pressure to obtain 7 mg of the target compound as a pale yellow solid in a 29% yield.

[0315] MS(m / z): 487 [M+1]

[0316]

[0317] 7-8) Step 8

[0318] 3-(2'-Chloro-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (6.5 mg, 0.013 mmol) obtained in step 7 above was dissolved in dimethyl sulfoxide (0.5 mL), and 4-methoxybenzylamine (17.0 μL, 0.13 mmol) was added dropwise at room temperature. The reaction mixture was stirred at 90°C for 2 hours. After the reaction was completed, the mixed solution was diluted with water and extracted with ethyl acetate, and the combined organic layer was dried over sodium sulfate and concentrated. The obtained residue was purified by MPLC (hexane: ethyl acetate = 3:7 (v / v)), and the solution was concentrated under reduced pressure to obtain 4 mg of the target compound as a pale yellow solid in a 52% yield.

[0319] MS(m / z): 588 [M+1]

[0320]

[0321] 7-9) Step 9

[0322] N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4methylphenyl)-3-(trifluoromethyl)benzamide (4 mg, 0.009 mmol) obtained in the above step 8 was dissolved in a solution of trifluoroacetic acid (0.2 mL), and then anisole (2.0 μL, 0.017 mmol) was added and stirred under reflux at 75°C for 3 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the obtained residue was purified by Prep HPLC (water: acetonitrile = 10 to 95%). The solution was concentrated under reduced pressure to obtain 1 mg of the target white solid compound (Compound 134, 3-(2'-amino-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidin]-6'(7'H)-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide) in a yield of 23%.

[0323] MS(m / z): 468 [M+1]

[0324] 1 H NMR (400 MHz, DMSO) δ 10.50 (s, 1H), 8.22 (s, 1H), 8.12 (s, 1H), 8.08 (d,J= 8.7 Hz, 1H), 7.96 (s, 1H), 7.91 (d,J= 7.8 Hz, 1H), 7.63 - 7.57 (m, 1H), 7.48 (dd,J= 17.5, 8.0 Hz, 2H), 6.67 (s, 2H), 4.91 (d,J= 15.3 Hz, 1H), 4.64 (d,J= 15.4 Hz, 1H), 2.19 (s, 3H), 1.65 - 1.49 (m, 4H).

[0325]

[0326] Information on the compound examples synthesized in the present invention is as follows: Tables 1 to 6.

[0327] Example Compound Structure Compound Name Synthetic Route 1 H NMR; MS[M+H]+1 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, MeOD) δ 8.25 (s, 1H), 8.19 (d, J = 7.8 Hz, 1H), 8.14 (s, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 2.0 Hz, 1H), 7.73 (t, J = 7.8 Hz, 1H), 7.57 (dd, J = 8.3, 2.0 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.72 (d, J = 15.7 Hz, 1H), 3.72 (t, J = 5.6 Hz, 2H), 3.54 (t, J = 5.6 Hz, 2H), 2.18 (s, 3H), 1.95 - 1.74 (m, 3H); 563.0[M+H]+2 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideC 1 H NMR (400 MHz, DMSO-d6) δ 10.51 (s, 1H), 8.29 (s, 1H), 8.25 (d, J = 8.1 Hz, 1H), 8.13 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.79 (t, J = 7.8) Hz, 1H), 7.72 (d, J = 2.1 Hz, 1H), 7.63 (dd, J = 8.3, 2.2 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 4.79 (d, J = 15.5 Hz, 1H), 4.62 (d, J = 15.5 Hz, 1H), 2.08 (s, 3H), 1.65 - 1.50 (m, 4H); 468.05 [M+H]3 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide B 1 H NMR (400 MHz, MeOD) δ 8.25 (s, 1H), 8.22 - 8.16 (m, J = 7.4 Hz, 2H), 7.90 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.73 (t, J = 7.8 Hz, 1H), 7.56 (dd, J = 8.3, 2.2 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 4.97 (d, J = 16.2 Hz, 1H), 4.75 (d, J = 16.2 Hz, 1H), 2.70 (ddd, J = 10.5, 6.9, 3.6 Hz, 1H), 2.19 (s, 3H), 1.96 - 1.79 (m, 4H), 0.96 - 0.83 (m, J = 6.9 Hz, 3H), 0.69 - 0.58 (m, 2H); 508.1[M+H]+4 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-fluoro-3-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, MeOD) δ 8.30 (d, J = 6.8 Hz, 1H), 8.28 - 8.21 (m, 1H), 8.13 (s, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.59 - 7.44 (m, 2H), 7.33 (d, J = 8.4 Hz, 1H), 4.96 (s, 1H), 4.73 (d, J = 15.9 Hz, 1H), 2.18 (s, 3H), 2.00 - 1.80 (m, 4H); 486.1[M+H]+5 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido]pyrimidine)-yl4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide C1 H NMR (400 MHz, DMSO-d6) δ 10.59 (s, 1H), 8.40 (d, J = 1.7 Hz, 1H), 8.25 (dd, J = 8.4, 1.8 Hz, 1H), 8.17 (s, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.61 (dd, J = 8.3, 2.0 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 4.80 (d, J = 15.5 Hz, 1H), 4.63 (d, J = 15.5 Hz, 1H), 2.09 (s, 3H), 1.79 - 1.48 (m, J = 13.9, 9.8, 6.0 Hz, 4H); 502.1[M+H]+6 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, MeOD) δ 9.37 (s, 1H), 8.54 (s, 1H), 8.47 (s, 1H), 8.32 (s, 1H), 8.11 (s, 1H), 7.92 (s, 1H), 7.80 (d, J = 2.1 Hz, 1H), 7.62 (dd, J = 8.3, 2.1 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 4.72 (d, J = 15.7 Hz, 1H), 2.45 (d, J = 0.8 Hz, 3H), 2.20 (s, 3H), 1.87 - 1.65 (m, 4H); 548.1[M+H]+7 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide C 1H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.14 (s, 2H), 8.07 (d, J = 9.1 Hz, 1H), 7.94 (d, J = 8.3 Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.61 (dd, J = 8.3, 2.1 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 4.79 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.5 Hz, 1H), 2.08 (s, 3H), 1.62 (m, 4H); 486.05 [M+H]8 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidini]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide B 1 H NMR (400 MHz, DMSO-d6) δ 10.65 (s, 1H), 9.50 (s, 1H), 8.57 (s, 1H), 8.42 (s, 2H), 8.15 (d, J = 24.9 Hz, 2H), 7.72 - 7.66 (m, 2H), 7.41 (s, 1H), 7.35 (d, J = 8.9 Hz, 1H), 4.80 (d, J = 15.3 Hz, 1H), 4.65 (d, J = 15.3 Hz, 1H), 2.34 (s, 3H), 2.10 (s, 3H), 1.77 - 1.48 (m, 4H), 0.65 (dd, J = 6.9, 2.3 Hz, 2H), 0.51 - 0.28 (m, 2H); 588.2[M+H]+9 N-(3-(2'-amino-7'-oxo-5'-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3, 4-difluorobenzamide C 1H NMR (400 MHz, MeOD) δ 8.13 (s, 1H), 7.88 (ddd, J = 11.2, 7.6, 2.2 Hz, 1H), 7.83 - 7.77 (m, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.53 (dd, J = 8.3, 2.2 Hz, 1H), 7.46 - 7.38 (m, 1H), 7.34 (d, J = 8.4 Hz, 1H), 4.94 (d, J = 16.1 Hz, 1H), 4.72 (d, J = 16.1 Hz, 1H), 2.18 (s, 3H), 1.93 - 1.79 (m, 4H); 436.15 [M+H]10 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,4-difluorobenzamide B 1 H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.16 (s, 1H), 8.02 (ddd, J = 11.5, 7.8, 2.1 Hz, 1H), 7.91 - 7.81 (m, 1H), 7.71 (d, J = 2.1 Hz, 1H), 7.66 - 7.57 (m, 2H), 7.36 - 7.25 (m, 2H), 4.80 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.5 Hz, 1H), 2.66 (dt, J = 10.8, 3.6 Hz, 1H), 2.08 (s, 3H), 1.70 - 1.51 (m, 4H), 0.68 - 0.60 (m, 2H), 0.50 - 0.38 (m, 2H); 476.2[M+H]+11 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide B 1H NMR (400 MHz, DMSO-d6) δ 10.40 (s, 1H), 8.17 (s, 1H), 7.72 (d, J = 2.1 Hz, 1H), 7.71 - 7.64 (m, 2H), 7.61 (dd, J = 8.3, 2.1 Hz, 1H), 7.52 (tt, J = 9.1, 2.3 Hz, 1H), 7.35 - 7.25 (m, 2H), 4.80 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.4 Hz, 1H), 2.66 (dt, J = 10.6, 3.5 Hz, 1H), 2.08 (s, 3H), 1.73 - 1.49 (m, 4H), 0.71 - 0.59 (m, 2H), 0.53 - 0.38 (m, 2H); 476.2[M+H]+12 N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide B 1 H NMR (400 MHz, DMSO-d6) δ 10.44 (s, 1H), 8.25 (s, 1H), 8.19 - 8.13 (m, 2H), 7.72 (d, J = 2.1 Hz, 1H), 7.67 - 7.60 (m, 2H), 7.31 (d, J = 8.5 Hz, 2H), 4.82 (d, J = 15.4 Hz, 1H), 4.63 (d, J = 15.4 Hz, 1H), 2.68 (dd, J = 3.6, 2.1 Hz, 1H), 2.53 (s, 3H), 2.09 (s, 3H), 1.72 - 1.50 (m, 4H), 0.68 - 0.62 (m, 2H), 0.47 - 0.42 (m, 2H); 522.2[M+H]+13 3-Bromo-N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)benzamide B 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.46 (s, 1H), 8.29 (s, 1H), 8.23 ​​(s, 1H), 8.17 (s, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.64 (dd, J = 8.3, 2.0 Hz, 1H), 7.33 (d, J = 8.5 Hz, 1H), 7.30 (d, J = 3.4 Hz, 1H), 4.81 (d, J = 15.4 Hz, 1H), 4.63 (d, J = 15.3 Hz, 1H), 2.67 (td, J = 7.0, 3.5 Hz, 1H), 2.09 (s, 3H), 1.72 - 1.50 (m, 4H), 0.72 - 0.59 (m, 2H), 0.53 - 0.39 (m, 2H); 586.1[M+H]+14 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2,4-difluorobenzamide C4 36.1 [M+H]+15 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide C436.1[M+H]+16 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxybenzamideC 1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 8.11 (s, 1H), 7.73 (s, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.48 (s, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.28 (d, J = 8.3 Hz, 1H), 7.15 (dd, J = 8.1, 1.7 Hz, 1H), 6.57 (s, 2H), 4.78 (d, J = 15.3 Hz, 1H), 4.60 (d, J = 15.3 Hz, 1H), 3.83 (s, 3H), 2.07 (s, 3H), 1.62 - 1.48 (m, 4H); 430.1[M+H]+17 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H-yl)-4-methylphenyl)-3-chloro-2-fluoro-5-(trifluoromethyl)benzamideC 1 H NMR (400 MHz, DMSO-d6) δ 11.01 (s, 1H), 8.42 (s, 1H), 8.13 (s, 1H), 8.06 (s, 1H), 7.65 (d, J = 1.9 Hz, 1H), 7.57 (dd, J = 8.3, 1.7 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 6.80 (s, 2H), 4.80 (d, J = 15.3 Hz, 1H), 4.62 (d, J = 15.0 Hz, 1H), 2.10 (s, 3H), 1.73 - 1.44 (m, 4H); 520.10 [M+H]+18 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-fluoro-5-(trifluoromethyl)benzamide C 1H NMR (400 MHz, DMSO-d6) δ 10.67 (s, 1H), 8.14 (s, 1H), 8.06 (dd, J = 6.0, 2.1 Hz, 1H), 8.02 - 7.95 (m, 1H), 7.72 (d, J = 2.1 Hz, 1H), 7.63 (t, J = 9.1 Hz, 1H), 7.51 (dd, J = 8.3, 2.2 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.89 (s, 2H), 4.79 (d, J = 15.5 Hz, 1H), 4.61 (d, J = 15.4 Hz, 1H), 2.08 (s, 3H), 1.70 - 1.48 (m, 4H); 486.15 [M+H]+19 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxy-5-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H), 8.15 (s, 1H), 7.87 (s, 1H), 7.79 (s, 1H), 7.72 (d, J = 2.0 Hz, 1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.48 (s, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.94 (s, 2H), 4.79 (d, J = 15.5 Hz, 1H), 4.62 (d, J = 15.5 Hz, 1H), 3.92 (s, 3H), 2.08 (s, 3H), 1.68 - 1.52 (m, 4H); 498.40 [M+H]+20 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4'-methoxy-5-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxyamide C 1H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.48 (s, 1H), 8.25 - 8.07 (m, 3H), 7.83 (d, J = 8.3 Hz, 2H), 7.72 (s, 1H), 7.68 (d, J = 9.1 Hz, 1H), 7.33 (d, J = 8.3 Hz, 1H), 7.10 (d, J = 8.3 Hz, 2H), 6.67 (s, 2H), 4.79 (d, J = 15.5 Hz, 1H), 4.62 (d, J = 14.7 Hz, 1H), 3.83 (s, 3H), 2.09 (s, 3H), 1.67 - 1.44 (m, 4H); 574.05 [M+H]+21 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-6-(trifluoromethyl)picolinamide C 1 H NMR (400 MHz, DMSO-d6) δ 10.47 (s, 1H), 8.42 - 8.32 (m, 2H), 8.18 (d, J = 7.0 Hz, 1H), 8.14 (s, 1H), 7.86 - 7.75 (m, 2H), 7.33 (d, J = 8.0 Hz, 1H), 6.95 (s, 2H), 4.82 (d, J = 15.3 Hz, 1H), 4.63 (d, J = 15.3 Hz, 1H), 2.09 (s, 3H), 1.71 - 1.49 (m, 4H); 469.25 [M+H]+22 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide C 1H NMR (400 MHz, DMSO-d6) δ 10.75 (s, 1H), 9.00 (s, 1H), 8.37 (s, 1H), 8.17 (d, J = 15.6 Hz, 2H), 7.74 (s, 1H), 7.63 (d, J = 7.2 Hz, 1H), 7.34 (d, J = 7.4 Hz, 1H), 6.94 (s, 2H), 4.79 (d, J = 15.4 Hz, 1H), 4.63 (d, J = 14.4 Hz, 1H), 2.09 (s, 3H), 1.75 - 1.45 (m, 4H); 469.25 [M+H]+23 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-hydroxy-5-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 10.43 (s, 1H), 8.14 (s, 1H), 7.73 (s, 2H), 7.61 (s, 2H), 7.30 (d, J = 7.9 Hz, 1H), 7.25 (s, 1H), 6.91 (s, 2H), 4.79 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.2 Hz, 1H), 2.08 (s, 3H), 1.72 - 1.46 (m, 4H); 484.20 [M+H]+24 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide C 1H NMR (400 MHz, DMSO-d6) δ 10.69 (s, 1H), 9.37 (d, J = 1.6 Hz, 1H), 9.19 (d, J = 1.2 Hz, 1H), 8.69 (s, 1H), 8.16 (s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.62 (dd, J = 8.3, 2.1 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.05 (s, 2H), 4.80 (d, J = 15.4 Hz, 1H), 4.63 (d, J = 15.5 Hz, 1H), 2.09 (s, 3H), 1.71 - 1.52 (m, 4H); 469.25 [M+H]+25 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-chloro-5-(trifluoromethyl)benzamideC 1 H NMR (400 MHz, DMSO-d6) δ 10.72 (s, 1H), 8.15 (s, 1H), 8.02 (s, 1H), 7.89 (dd, J = 8.5, 1.4 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.74 (d, J = 1.4 Hz, 1H), 7.48 (dd, J = 8.3, 1.5 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.94 (s, 2H), 4.79 (d, J = 15.4 Hz, 1H), 4.61 (d, J = 15.4 Hz, 1H), 2.08 (s, 3H), 1.75 - 1.46 (m, 4H); 502.15 [M+H]+26 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-chloro-5-(trifluoromethyl)benzamide C 1H NMR (400 MHz, DMSO-d6) δ 10.60 (s, 1H), 8.32 (s, 1H), 8.25 (s, 1H), 8.17 (s, 1H), 8.14 (s, 1H), 7.73 (d, J = 2.1 Hz, 1H), 7.62 (dd, J = 8.3, 2.1 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.10 (s, 2H), 4.80 (d, J = 15.5 Hz, 1H), 4.63 (d, J = 15.5 Hz, 1H), 2.09 (s, 3H), 1.72 - 1.52 (m, 4H); 502.15 [M+H]+27 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide B 1 H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.18 (s, 1H), 8.12 (d, J = 9.2 Hz, 1H), 8.00 (d, J = 8.3 Hz, 1H), 7.72 (d, J = 1.1 Hz, 1H), 7.64 (dd, J = 8.4, 1.4 Hz, 1H), 7.43 - 7.28 (m, 2H), 4.81 (d, J = 15.4 Hz, 1H), 4.63 (d, J = 15.3 Hz, 1H), 2.66 (dt, J = 10.8, 3.6 Hz, 1H), 2.09 (s, 3H), 1.72 - 1.47 (m, 4H), 0.70 - 0.56 (m, 2H), 0.49 - 0.35 (m, 2H); 526.30 [M+H]+28 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide B 1H NMR (400 MHz, DMSO-d6) δ 10.39 (s, 1H), 8.17 (s, 1H), 7.72 (s, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.67 - 7.64 (m, 1H), 7.41 (d, J = 11.2 Hz, 2H), 7.31 (d, J = 8.4 Hz, 1H), 4.81 (d, J = 15.5 Hz, 1H), 4.63 (d, J = 15.5 Hz, 1H), 3.82 - 3.71 (m, 4H), 3.49 - 3.35 (m, 1H), 3.33 - 3.22 (m, 4H), 2.09 (s, 3H), 1.70 - 1.50 (m, J = 15.5, 8.9 Hz, 4H), 0.65 (td, J = 6.8, 4.7 Hz, 2H), 0.49 - 0.38 (m, 2H); 593.15 [M+H]+29 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, DMSO-d6) δ 10.39 (s, 1H), 8.13 (s, 1H), 7.71 (s, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.67 - 7.62 (m, 2H), 7.39 (s, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.75 (s, 2H), 4.78 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.4 Hz, 1H), 3.82 - 3.72 (m, 4H), 3.31 - 3.27 (m, 4H), 2.08 (s, 3H), 1.66 - 1.50 (m, 4H); 553.20 [M+H]+30 N-(3-(2'-(cycloamino)-7'-oxo-5' H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide B1 H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.18 (s, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.45 (d, J = 2.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 1H), 7.09 (s, 1H), 4.81 (d, J = 15.5 Hz, 1H), 4.63 (d, J = 15.5 Hz, 1H), 3.63 (t, J = 5.4 Hz, 2H), 3.52 (t, J = 5.4) Hz, 2H), 3.49 - 3.35 (m, 1H), 3.25 (s, 3H), 3.03 (s, 3H), 2.08 (s, 3H), 1.69 - 1.51 (m, 4H), 0.69 - 0.60 (m, 2H), 0.50 - 0.40 (m, 2H); 595.25 [M+H]+31 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.14 (s, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.3, 2.1 Hz, 1H), 7.45 (d, J = 2.5 Hz, 2H), 7.30 (d, J = 8.4 Hz, 1H), 7.09 (s, 1H), 6.83 (s, 2H), 4.79 (d, J = 15.5 Hz, 1H), 4.62 (d, J = 15.5 Hz, 1H), 3.63 (t, J = 5.4 Hz, 2H), 3.52 (t, J = 5.4 Hz, 2H), 3.25 (s, 3H), 3.03 (s, 3H), 2.08 (s, 3H), 1.67 - 1.51 (m, 4H); 555.15 [M+H]+32 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide B 1 H NMR (400 MHz, DMSO-d6) δ 10.41 (s, 1H), 9.72 (s, 1H), 8.17 (s, 1H), 7.76 (s, 1H), 7.73 (s, 1H), 7.69 - 7.62 (m, 2H), 7.51 (s, 1H), 7.36 (d, J = 2.7 Hz, 1H), 7.32 (d, J = 9.2 Hz, 1H), 4.84 (d, J = 15.7 Hz, 1H), 4.67 (d, J = 15.8 Hz, 1H), 4.05 (d, J = 11.3 Hz, 2H), 3.51 (d, J = 10.6 Hz, 2H), 3.26 - 2.95 (m, 5H), 2.83 (s, 3H), 2.04 (s, 3H), 1.86 - 1.61 (m, 4H), 0.70 - 0.59 (m, 2H), 0.49 - 0.37 (m, 2H); 606.25 [M+H]+33 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide C 1H NMR (400 MHz, DMSO-d6) δ 10.37 (s, 1H), 8.11 (s, 1H), 7.72 (d, J = 1.5 Hz, 1H), 7.67 (s, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.40 (s, 2H), 7.31 (d, J = 9.1 Hz, 1H), 6.57 (s, 2H), 4.77 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.5 Hz, 1H), 4.09 (d, J = 9.5 Hz, 2H), 3.55 (d, J = 9.5 Hz, 2H), 3.16 - 3.09 (m, 4H), 2.88 (s, 3H), 2.09 (s, 3H), 1.64 - 1.48 (m, 4H); 566.10 [M+H]+34 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, DMSO-d6) δ 10.44 (s, 1H), 8.12 (s, 1H), 7.74 (s, 1H), 7.72 (s, 1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.49 (s, 1H), 7.32 (d, J = 8.1 Hz, 1H), 4.77 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.4 Hz, 1H), 3.61 - 3.52 (m, J = 4.5 Hz, 4H), 3.30 - 3.20 (m, 4H), 2.08 (s, 3H), 1.66 - 1.47 (m, 4H); 552.20 [M+H]35 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide B 1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H), 8.18 (s, 1H), 7.75 (s, 1H), 7.72 (s, 1H), 7.67 (s, 1H), 7.50 (s, 1H), 7.44 (s, 1H), 7.32 (d, J = 8.3 Hz, 1H), 4.80 (d, J = 15.5 Hz, 1H), 4.64 (d, J = 15.5 Hz, 1H), 3.88 (s, 1H), 3.54 - 3.53 (m, 4H), 3.33 - 3.19 (m, 4H), 2.09 (s, 3H), 1.70 - 1.50 (m, J = 16.3, 8.3 Hz, 4H), 0.73 - 0.60 (m, 2H), 0.52 - 0.37 (m, 2H); 592.35 [M+H]+36 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1, 8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyl)(methyl)amino)-5-(trifluoromethyl)benzamide B 1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 8.17 (s, 1H), 7.70 (s, 1H), 7.65 (dd, J = 8.3, 2.0 Hz, 1H), 7.55 (s, 1H), 7.50 (s, 1H), 7.47 (s, 1H), 7.31 (d, J = 8.5 Hz, 1H), 4.79 (d, J = 15.4 Hz, 1H), 4.63 (d, J = 15.4 Hz, 1H), 3.84 - 3.73 (m, 2H), 3.30 - 3.21 (m, 2H), 3.04 (s, 6H), 3.01 (s, 3H), 2.69 - 2.62 (m, 132H), 2.33 (s, 19H), 2.08 (s, 3H), 1.99 (d, J = 8.6 Hz, 83H), 1.59 (dd, J = 15.3, 7.8 Hz, 4H), 0.64 (td, J = 6.8, 4.9 Hz, 2H), 0.46 - 0.40 (m, 2H); 608.25 [M+H]+37 N-(3-(2'-Amino-7'-oxo-5'H-spiro [cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyl l)(methylamino)-5-(trifluoromethyl)benzamide C6 12.25 [M+H]+38 N-(4-methyl-3-(2'-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 9.62 (s, 1H), 9.44 (s, 1H), 8.30 (s, 2H), 8.26 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.89 - 7.74 (m, 2H), 7.63 (dd, J = 8.3, 2.0 Hz, 1H), 7.60 (d, J = 9.1 Hz, 2H), 7.32 (d, J = 8.5 Hz, 1H), 6.96 (d, J = 9.1 Hz, 2H), 4.87 (d, J = 15.7 Hz, 1H), 4.69 (d, J = 15.7 Hz, 1H), 3.74 (d, J = 13.4 Hz, 2H), 3.51 (d, J = 12.1 Hz, 2H), 3.18 - 3.10 (m, 2H), 2.94 - 2.80 (m, 5H), 2.10 (s, 3H), 1.72 - 1.50 (m, 4H); 642.00 [M+H]+39 N-(3-(2'-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 9.45 (s, 1H), 8.30 (s, 2H), 8.26 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.79 (t, J = 7.9) Hz, 1H), 7.76 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 8.3, 2.1 Hz, 1H), 7.60 (d, J = 8.9 Hz, 2H), 7.33 (d, J = 8.5 Hz, 1H), 6.99 (d, J = 8.7 Hz, 2H), 4.87 (d, J = 15.6 Hz, 1H), 4.70 (d, J = 15.6 Hz, 1H), 3.63 - 3.58 (m, 4H), 3.16 - 3.02 (m, 4H), 2.11 (s, 3H), 2.04 (s, 3H), 1.77 - 1.54 (m, 4H); 670.05 [M+H]+40 N-(4-methyl-3-(2'-((4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 9.41 (s, 1H), 8.30 (d, J = 2.3 Hz, 2H), 8.26 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.7 Hz, 1H), 7.79 (t, J = 7.8 Hz, 1H), 7.76 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 8.3, 2.1 Hz, 1H), 7.58 (d, J = 8.9 Hz, 2H), 7.33 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 8.8 Hz, 2H), 4.87 (d, J = 15.6 Hz, 1H), 4.69 (d, J = 15.7 Hz, 1H), 3.80 - 3.68 (m, 4H), 3.14 - 2.98 (m, 4H), 2.10 (s, 3H), 1.76 - 1.53 (m, 4H); 629.05 [M+H]+41 N-(4-methyl-3-(2'-((4-(4-methylpiperazine-1-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 9.94 (s, 1H), 9.76 (s, 1H), 8.40 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.85 - 7.76 (m, 4H), 7.63 (dd, J = 8.3, 2.1 Hz, 1H), 7.43 (d, J = 8.7 Hz, 2H), 7.34 (d, J = 8.5 Hz, 1H), 4.92 (d, J = 15.9 Hz, 1H), 4.75 (d, J = 15.9 Hz, 1H), 4.22 (s, 4H), 3.18 - 2.98 (m, 4H), 2.83 (s, 3H), 2.11 (s, 3H), 1.77 - 1.63 (m, 4H); 670.00 [M+H]+42 N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 9.40 (s, 1H), 8.30 (s, 1H), 8.26 (t, J = 3.8 Hz, 2H), 7.98 (d, J = 9.5 Hz, 2H), 7.83 - 7.74 (m, 3H), 7.63 (dd, J = 8.3, 2.1 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 6.72 (d, J = 2.5 Hz, 1H), 6.57 (dd, J = 8.8, 2.5 Hz, 1H), 4.87 (d, J = 15.7) Hz, 1H), 4.69 (d, J = 15.8 Hz, 1H), 3.85 (d, J = 12.6 Hz, 5H), 3.58 (d, J = 11.8 Hz, 2H), 3.26 - 3.19 (m, 2H), 3.13 (dd, J = 21.0, 9.4 Hz, 2H), 2.94 (t, J = 11.8 Hz, 2H), 2.10 (s, 3H), 1.69 - 1.53 (m, 4H), 1.26 (t, J = 7.3 Hz, 3H); 686.15 [M+H]+43 N-(4-methyl-3-(2'-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 9.76 (s, 1H), 8.37 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 7.9 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.83 - 7.77 (m, 2H), 7.75 (d, J = 8.5 Hz, 2H), 7.63 (dd, J = 8.3, 2.1 Hz, 1H), 7.36 - 7.26 (m, 3H), 4.92 (d, J = 15.8 Hz, 1H), 4.74 (d, J = 15.9 Hz, 1H), 4.37 (s, 2H), 3.67 (s, 4H), 3.24 (s, 4H), 2.89 (s, 3H), 2.11 (s, 3H), 1.82 - 1.56 (m, 4H); 656.15 [M+H]+44 N-(3-(2'-((4-(1H-imidazol-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 10.00 (s, 1H), 9.47 (s, 1H), 8.42 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.18 (s, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 9.1 Hz, 2H), 7.83 (s, 1H), 7.82 - 7.77 (m, 2H), 7.72 (d, J = 9.1 Hz, 2H), 7.63 (dd, J = 8.3, 2.1 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 4.93 (d, J = 15.9 Hz, 1H), 4.75 (d, J = 15.9 Hz, 1H), 2.11 (s, 3H), 1.77 - 1.64 (m, 4H); 610.10 [M+H]+45 N-(4-methyl-3-(7'-oxo-2'-((4-(piperazin-1-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 9.44 (s, 1H), 8.69 (s, 2H), 8.30 (s, 2H), 8.26 (d, J = 7.9 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 2.1 Hz, 1H), 7.63 (dd, J = 8.3, 2.1 Hz, 1H), 7.60 (d, J = 9.1 Hz, 2H), 7.33 (d, J = 8.5 Hz, 1H), 6.96 (d, J = 9.1 Hz, 2H), 4.88 (d, J = 15.7 Hz, 1H), 4.70 (d, J = 15.7 Hz, 1H), 3.26 (s, 8H), 2.10 (s, 3H), 1.75 - 1.56 (m, 4H); 628.15 [M+H]+46 (S)-N-(3-(2'-((4-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMF-d7) δ 11.33 (s, 1H), 10.55 (s, 1H), 9.16 (s, 1H), 8.31 - 8.20 (m, 3H), 7.87 - 7.79 (m, 2H), 7.71 (t, J = 7.8 Hz, 1H), 7.63 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 8.9 Hz, 2H), 7.22 (d, J = 8.4 Hz, 1H), 6.54 (d, J = 9.0 Hz, 2H), 4.85 (d, J = 15.5 Hz, 1H), 4.65 (d, J = 15.5 Hz, 1H), 4.07 (s, 1H), 3.65 - 3.52 (m, 2H), 3.42 (dd, J = 8.9, 6.1 Hz, 1H), 3.18 (dd, J = 16.9, 8.2 Hz, 1H), 2.69 (d, J = 5.2 Hz, 1H), 2.51 - 2.38 (m, 1H), 2.36 - 2.23 (m, 1H), 2.09 - 1.96 (m, 4H); 656.2 [M+H]+47 N-(4-methyl-3-(7'-oxo-2'-((4-(piperidin-4-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, MeOD) δ 8.26 (s, 2H), 8.20 (d, J = 7.7 Hz, 1H), 7.90 (d, J = 7.9 Hz, 1H), 7.74 (t, J = 7.9 Hz, 1H), 7.64 (d, J = 8.6 Hz, 2H), 7.59 (dd, J = 8.3, 2.2 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 8.6 Hz, 2H), 4.98 (d, J = 15.6 Hz, 1H), 4.76 (d, J = 15.8 Hz, 1H), 3.50 (d, J = 13.3 Hz, 2H), 3.14 (dd, J = 13.1, 10.3 Hz, 2H), 2.88 (dd, J = 13.8, 10.5 Hz, 1H), 2.09 (d, J = 14.4 Hz, 2H), 1.96 - 1.87 (m, 2H), 1.86 - 1.71 (m, 4H); 527.5 [M+H]+48 N-(4-methyl-3-(2'-((3-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, MeOD) δ 8.25 (s, 2H), 8.20 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 2.2 Hz, 1H), 7.73 (t, J = 7.8 Hz, 1H), 7.58 (dd, J = 8.3, 2.1 Hz, 1H), 7.54 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 6.68 (dd, J = 8.0, 1.6 Hz, 1H), 4.96 (d, J = 15.8 Hz, 1H), 4.75 (d, J = 15.8 Hz, 1H), 3.86 (d, J = 12.7 Hz, 2H), 3.62 (d, J = 11.7 Hz, 2H), 3.30 - 3.21 (m, J = 11.8 Hz, 2H), 3.07 (t, J = 12.3 Hz, 2H), 2.98 (s, 3H), 2.19 (s, 3H), 1.90 - 1.72 (m, 4H); 542.3 [M+H]+49 N-(3-(2'-((4-(1-acetylpiperidin-4-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.60 - 10.47 (m, 6H), 9.56 (s, 1H), 8.32 (d, J = 9.7 Hz, 2H), 8.26 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.79 (t, J = 7.9 Hz, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.64 (dd, J = 13.0, 5.3 Hz, 3H), 7.33 (d, J = 8.5 Hz, 1H), 7.15 (d, J = 8.6 Hz, 2H), 4.88 (d, J = 15.7 Hz, 1H), 4.71 (d, J = 15.8 Hz, 1H), 4.51 (d, J = 13.1 Hz, 1H), 3.90 (d, J = 13.5 Hz, 1H), 3.10 (t, J = 11.9 Hz, 1H), 2.71 - 2.62 (m, 1H), 2.61 - 2.54 (m, 1H), 2.10 (s, 3H), 2.02 (s, 3H), 1.84 - 1.61 (m, 6H), 1.60 - 1.49 (m, 1H), 1.46 - 1.34 (m, 1H); 669.2 [M+H]+50 N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide B 1H NMR (400 MHz, MeOD) δ 9.39 (d, J = 2.5 Hz, 1H), 8.44 (s, 1H), 8.41 (d, J = 2.5 Hz, 1H), 8.28 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.83 - 7.78 (m, 1H), 7.78 (s, 1H), 7.57 (dd, J = 8.3, 2.1 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 5.05 (d, J = 16.2 Hz, 1H), 4.85 (d, J = 6.2 Hz, 1H), 3.87 (s, 2H), 3.49 (d, J = 11.8 Hz, 2H), 3.16 (dd, J = 28.7, 17.9 Hz, 2H), 3.08 - 2.97 (m, 2H), 2.91 (s, 3H), 2.71 (s, 6H), 2.52 (t, J = 11.8 Hz, 2H), 2.21 (s, 3H), 2.16 (s, 2H), 1.94 - 1.79 (m, 4H); 671.20 [M+H]+51 N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H), 10.36 (s, 1H), 9.11 (s, 1H), 8.47 (s, 1H), 8.34 (d, J = 8.9 Hz, 1H), 8.31 (s, 1H), 8.27 (d, J = 7.6 Hz, 1H), 7.99 (d, J = 7.6 Hz, 1H), 7.84 - 7.75 (m, 2H), 7.71 (d, J = 7.4 Hz, 1H), 7.63 (dd, J = 8.3, 2.0 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 4.96 (d, J = 16.2 Hz, 1H), 4.78 (d, J = 16.1 Hz, 1H), 2.59 (s, 3H), 2.11 (s, 3H), 1.82 -1.63 (m, 4H); 559.2 [M+H]+52 N-(4-methyl-3-(2'-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 9.55 (s, 1H), 8.29 (s, 2H), 8.25 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.94 (s, 1H), 7.79 (t, J = 7.8 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.68 - 7.61 (m, 2H), 7.32 (d, J = 8.5 Hz, 1H), 5.55 (dd, J = 14.0, 7.2 Hz, 1H), 4.95 - 4.81 (m, J = 18.0, 6.2 Hz, 5H), 4.69 (d, J = 15.7 Hz, 1H), 2.10 (s, 3H); 590.2 [M+H]+53 N-(3-(2'-((2-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 7.7 Hz, 2H), 8.02 (s, 1H), 7.98 (d, J = 7.6 Hz, 1H), 7.79 (t, J = 7.8) Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 6.52 (dd, J = 8.8, 2.3 Hz, 1H), 4.86 (d, J = 15.7 Hz, 1H), 4.68 (d, J = 15.7 Hz, 1H), 3.82 (s, 3H), 3.78 - 3.70 (m, 4H), 3.14 - 3.07 (m, 4H), 2.09 (s, 3H), 1.68 - 1.53 (m, 4H); 659.05 [M+H]+54 N-(3-(2'-((2-methoxy-4-(morpholine-4-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.38 (s, 1H), 8.31 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 8.23 ​​(d, J = 8.2 Hz, 1H), 8.16 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H), 7.65 (dd, J = 8.2, 2.1 Hz, 1H), 7.33 (d, J = 8.6 Hz, 1H), 7.09 (d, J = 1.6 Hz, 1H), 7.04 (dd, J = 8.2, 1.6 Hz, 1H), 4.92 (d, J = 16.0 Hz, 1H), 4.74 (d, J = 15.9 Hz, 1H), 3.90 (s, 3H), 3.61 (s, 4H), 3.52 (s, 4H), 2.11 (s, 3H), 1.73 - 1.62 (m, 4H); 687.05 [M+H]+55 N-(3-(2'-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 9.56 (s, 1H), 9.47 (s, 1H), 8.34 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 7.7 Hz, 1H), 7.83 - 7.76 (m, 2H), 7.63 (dd, J = 8.3, 2.0 Hz, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.18 (dd, J = 9.1, 1.8 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 4.93 (d, J = 15.8 Hz, 1H), 4.74 (d, J = 15.9 Hz, 1H), 3.84 (s, 3H), 3.51 (t, J = 14.5 Hz, 4H), 3.24 (t, J = 11.5 Hz, 2H), 2.95 (d, J = 11.2 Hz, 2H), 2.89 (s, 3H), 2.13 (s, 3H), 1.86 - 1.60 (m, 4H); 672.05 [M+H]+56 N-(3-(2'-((3-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 9.58 (s, 1H), 8.34 (s, 1H), 8.31 (s, 1H), 8.26 (d, J = 7.7 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.79 (dd, J = 12.9, 4.9 Hz, 2H), 7.68 - 7.56 (m, 2H), 7.33 (d, J = 8.5 Hz, 1H), 7.17 (dd, J = 9.4, 1.5 Hz, 1H), 6.94 (s, 1H), 4.89 (d, J) = 15.8 Hz, 1H), 4.72 (d, J = 15.6 Hz, 1H), 3.83 (s, 3H), 3.75 (s, 4H), 3.00 (s, 4H), 2.11 (s, 3H), 1.79 - 1.59 (m, 4H); 659.00 [M+H]+57 N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 9.79 (s, 1H), 9.46 (s, 1H), 8.35 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.82 - 7.73 (m, 2H), 7.68 (dd, J = 15.3, 2.2 Hz, 1H), 7.63 (dd, J = 8.3, 2.1 Hz, 1H), 7.44 (dd, J = 8.8, 1.7 Hz, 1H), 7.31 (d, J = 8.5 Hz, 1H), 7.11 - 7.02 (m, 1H), 4.90 (d, J = 15.8 Hz, 1H), 4.72 (d, J = 15.8 Hz, 1H), 3.56 (d, J = 11.6 Hz, 2H), 3.43 (d, J = 12.9 Hz, 2H), 3.29 - 3.08 (m, 4H), 2.99 (t, J = 11.7 Hz, 2H), 2.10 (s, 3H), 1.81 - 1.58 (m, 4H), 1.24 (t, J = 7.3 Hz, 3H); 674.10 [M+H]+58 N-(3-(2'-((6-(4-ethylpiperazin-1-yl)-2-methoxypyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 9.54 (s, 1H), 8.39 (s, 1H), 7.30 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 3.0 Hz, 1H), 6.98 (d, J = 7.5) Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.82 - 6.72 (m, 2H), 6.62 (dd, J = 8.3, 2.0 Hz, 1H), 6.32 (d, J = 8.6 Hz, 1H), 5.49 (d, J = 8.6 Hz, 1H), 4.89 (d, J = 15.9 Hz, 1H), 4.70 (d, J = 15.9 Hz, 1H), 4.37 (d, J = 12.2 Hz, 2H), 3.85 (s, 3H), 3.58 (d, J = 10.7 Hz, 2H), 3.25 - 2.98 (m, 6H), 2.09 (s, 3H), 1.78 - 1.59 (m, 4H), 1.25 (t, J = 7.3 Hz, 3H); 687.95 [M+H]+59 N-(4-methyl-3-(7'-oxo-2'-(phenylamino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 9.85 (s, 1H), 8.39 (s, 1H), 8.33 (s, 1H), 8.29 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.80 (dd, J = 13.5, 5.0 Hz, 2H), 7.72 (d, J = 7.8 Hz, 2H), 7.68 (dd, J = 8.3, 2.0 Hz, 1H), 7.37 - 7.29 (m, 3H), 7.00 (t, J = 7.3 Hz, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.75 (d, J = 15.8 Hz, 1H), 2.13 (s, 3H), 1.81 - 1.66 (m, 4H); 544.10 [M+H]+60 N-(3-(2'-((4-(4-(dimethylaminopiperidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 9.42 (s, 1H), 8.35 - 8.21 (m, 3H), 7.98 (d, J = 8.0 Hz, 1H), 7.83 - 7.75 (m, 2H), 7.63 (dd, J = 8.3, 2.0 Hz, 1H), 7.56 (d, J = 9.0 Hz, 2H), 7.33 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 9.0 Hz, 2H), 4.87 (d, J = 15.6 Hz, 1H), 4.70 (d, J = 15.7 Hz, 1H), 3.75 (d, J = 12.5 Hz, 2H), 3.49 - 3.35 (m, 3H), 2.79 (d, J = 4.9 Hz, 6H), 2.27 (d, J = 11.0 Hz, 2H), 2.10 (s, 3H), 2.00 (d, J = 10.9 Hz, 2H), 1.78 - 1.59 (m, 4H); 670.25 [M+H]+61 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide C 1H NMR (400 MHz, MeOD) δ 8.29 (s, 1H), 8.19 (d, J = 8.1 Hz, 1H), 8.13 (s, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.78 (d, J = 2.0 Hz, 1H), 7.57 (dd, J = 8.3, 2.1 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 4.95 (s, 1H), 4.73 (d, J = 15.8 Hz, 1H), 3.87 (s, 2H), 3.50 (d, J = 12.0 Hz, 2H), 3.19 (t, J = 11.3 Hz, 2H), 3.05 (d, J = 12.8 Hz, 2H), 2.92 (s, 3H), 2.51 (t, J = 12.0 Hz, 2H), 2.19 (s, 3H), 1.93 - 1.76 (m, 4H); 580.3 [M+H]+62 N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide B 1 H NMR (400 MHz, DMSO-d6) δ 10.49 (s, 1H), 9.76 (s, 1H), 8.30 (s, 1H), 8.29 - 8.25 (m, 1H), 8.18 (s, 1H), 7.72 (d, J = 1.9 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 8.3, 2.0 Hz, 1H), 7.46 (s, 1H), 7.32 (d, J = 8.6 Hz, 1H), 4.91 (d, J = 15.9 Hz, 1H), 4.72 (d, J = 15.7 Hz, 1H), 3.55 (d, J = 8.4 Hz, 2H), 3.26 - 3.10 (m, 7H), 2.91 (s, 3H), 2.09 (s, 3H), 1.91 - 1.72 (m, 4H), 0.70 - 0.61 (m, 2H), 0.52 - 0.40 (m, 2H); 606.55 [M+H]+63 N-(3-(2'-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H), 10.00 (s, 1H), 9.60 (s, 1H), 8.31 (d, J = 10.5 Hz, 2H), 8.26 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.76 (t, J = 7.8 Hz, 1H), 7.62 (dd, J = 8.3, 2.0 Hz, 1H), 7.56 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.5 Hz, 1H), 6.99 (d, J = 8.7 Hz, 2H), 4.90 (d, J = 15.6 Hz, 1H), 4.71 (d, J = 15.7 Hz, 1H), 3.75 - 3.60 (m, 2H), 3.30 - 3.15 (m, 2H), 2.96 (s, 3H), 2.83 (s, 6H), 2.10 (s, 3H), 1.85 - 1.60 (m, 4H); 644.10 [M+H]+64 N-(4-methyl-3-(7'-oxo-2'-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 9.63 (s, 1H), 8.31 (s, 2H), 8.27 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 7.7 Hz, 2H), 7.80 (t, J = 8.0) Hz, 1H), 7.77 (d, J = 1.9 Hz, 1H), 7.65 (dd, J = 8.3, 2.0 Hz, 1H), 7.61 (s, 1H), 7.33 (d, J = 8.4 Hz, 1H), 5.13 (dd, J = 18.2, 9.4 Hz, 2H), 4.88 (d, J = 15.6 Hz, 1H), 4.71 (d, J = 15.6 Hz, 1H), 2.11 (s, 3H), 1.80 - 1.55 (m, 4H); 616.00 [M+H]+

[0328] Example Compound Structure Compound Name Synthetic Route 1 H NMR; MS[M+H]+65 N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide C 1 H NMR (400 MHz, DMSO-d6) δ 10.49 (s, 1H), 9.76 (s, 1H), 8.30 (s, 1H), 8.29 - 8.24 (m, 1H), 8.14 (s, 1H), 7.72 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 8.2, 2.0 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 6.80 (s, 2H), 4.78 (d, J = 15.4 Hz, 1H), 4.62 (d, J = 15.5 Hz, 1H), 3.31 - 3.04 (m, J = 20.4, 9.9 Hz, 8H), 2.91 (d, J = 2.9 Hz, 3H), 2.09 (s, 3H), 1.72 - 1.44 (m, 4H); 566.25 [M+H]+66 N-(3-(2'-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.30 (s, 1H), 8.26 (s, 1H), 8.01 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.79 (t, J = 7.9 Hz, 1H), 7.75 (s, 1H), 7.72 (s, 1H), 7.67 - 7.62 (m, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.69 (s, 1H), 6.53 (d, J = 8.5 Hz, 1H), 4.86 (d, J = 15.5 Hz, 1H), 4.69 (d, J = 15.7 Hz, 1H), 3.82 (s, 3H), 3.18 - 3.11 (m, 4H), 3.11 - 3.05 (m, 4H), 2.24 (s, 3H), 1.92 (s, 3H), 1.70 - 1.52 (m, 4H); 699.95[M+H]+67 N-(3-(2'-((3-methoxy-4-(piperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 9.56 (s, 1H), 8.82 (s, 2H), 8.33 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.82 - 7.75 (m, J = 8.5, 4.9 Hz, 1H), 7.69 - 7.62 (m, 1H), 7.60 (s, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 4.88 (d, J = 15.8 Hz, 1H), 4.71 (d, J = 15.7 Hz, 1H), 3.81 (s, 3H), 3.22 (s, 4H), 3.09 (s, 4H), 2.10 (s, 3H), 1.75 - 1.59 (m, 4H); 658.6 [M+H]+68 N-(3-(2'-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H), 9.08 (s, 1H), 8.46 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.98 (d, J = 7.2 Hz, 1H), 7.82 - 7.79 (m, 1H), 7.71 - 7.57 (m, J = 8.3 Hz, 2H), 7.34 (d, J = 8.5 Hz, 1H), 4.95 (d, J = 16.0 Hz, 1H), 4.77 (d, J = 16.2 Hz, 1H), 3.32 (s, 14H), 2.57 (s, 3H), 2.11 (s, 3H), 1.80 - 1.64 (m, 4H); 560.0 [MH]+69 N-(3-(2'-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A 1 H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.30 (s, 1H), 8.26 (d, J = 7.9 Hz, 1H), 8.20 (s, 1H), 8.12 (s, 1H), 7.97 (d, J = 7.7 Hz, 1H), 7.79 (t, J = 7.8 Hz, 1H), 7.74 (s, 1H), 7.67 - 7.61 (m, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.33 (d, J = 8.5 Hz, 1H), 4.84 (d, J = 15.6 Hz, 1H), 4.66 (d, J = 15.6 Hz, 1H), 3.81 (s, 3H), 2.54 - 2.42 (m, 4H), 2.43 - 2.37 (m, 4H), 2.21 (s, 3H), 1.89 (s, 3H), 1.69 - 1.49 (m, J = 34.3, 23.5, 6.8 Hz, 4H); 673.05 [M+H]+70 N-(3-(2'-((2-hydroxy)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide B 1H NMR (400 MHz, MeOD) δ 8.25 (s, 1H), 8.19 (d, J = 7.8 Hz, 1H), 8.14 (s, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 2.0 Hz, 1H), 7.73 (t, J = 7.8 Hz, 1H), 7.57 (dd, J = 8.3, 2.0 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.72 (d, J = 15.7 Hz, 1H), 3.72 (t, J = 5.6 Hz, 2H), 3.54 (t, J = 5.6 Hz, 2H), 2.18 (s, 3H), 1.95 - 1.74 (m, 3H); 512.1 [M+H]+71 1-(4-fluorophenyl)-3-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)urea A 1 H NMR (400 MHz, MeOD) δ 8.73 (d, J = 2.5 Hz, 1H), 8.25 (s, 1H), 8.05 (dd, J = 8.5, 2.6 Hz, 1H), 7.51 (s, 1H), 7.44 - 7.33 (m, 2H), 7.28 - 7.17 (m, J = 8.7 Hz, 3H), 7.05 - 6.95 (m, 2H), 4.91 (d, J = 15.8 Hz, 1H), 4.71 (d, J = 15.9 Hz, 1H), 2.47 (s, 3H), 2.16 (s, 1H), 2.13 (s, 3H), 1.83 - 1.72 (m, 4H); 524.20 [M+H]+72 4-chloro-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)benzamide A 1H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 9.12 (s, 1H), 8.47 (s, 1H), 8.35 (d, J = 7.2 Hz, 1H), 7.98 (d, J = 8.5 Hz, 2H), 7.82 (s, 1H), 7.72 (d, J = 7.5 Hz, 1H), 7.66 - 7.54 (m, 3H), 7.32 (d, J = 7.5 Hz, 1H), 4.95 (d, J = 15.3 Hz, 1H), 4.77 (d, J = 15.9 Hz, 1H), 2.60 (s, 3H), 2.10 (s, 3H), 1.82 - 1.64 (m, 4H); 526.15 [M+H]+73 N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)thiophene-2-carboxamide A 1 H NMR (400 MHz, MeOD) δ 9.42 (d, J = 2.3 Hz, 1H), 8.47 - 8.39 (m, 2H), 7.92 (d, J = 3.8 Hz, 1H), 7.83 - 7.79 (m, 2H), 7.76 (d, J = 4.2 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.21 (dd, J = 4.9, 3.9 Hz, 1H), 5.07 (d, J = 16.1 Hz, 2H), 4.85 (d, J = 16.2 Hz, 1H), 2.73 (d, J = 5.7 Hz, 6H), 1.95 - 1.77 (m, 4H); 497.20 [M+H]+74 N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)furan-2-carboxamide A 1H NMR (400 MHz, MeOD) δ 9.44 (d, J = 2.5 Hz, 1H), 8.44 (dd, J = 9.4, 3.1 Hz, 2H), 7.84 - 7.79 (m, 2H), 7.78 (s, 1H), 7.60 - 7.55 (m, 1H), 7.37 (d, J = 8.5 Hz, 1H), 7.29 (d, J = 3.4 Hz, 1H), 6.67 (dd, J = 3.4, 1.7 Hz, 1H), 5.07 (d, J = 15.9 Hz, 1H), 4.85 (d, J = 16.0 Hz, 1H), 2.74 (d, J = 5.4 Hz, 5H), 1.95 - 1.81 (m, 4H); 481.20 [M+H]+

[0329] Example Compound Structure Compound Name Synthetic Route 1 H NMR; MS[M+H]+75 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclobutanecarboxamide C378.05[M+H]76 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-oxocyclobutane-1-carboxamide C392.10[M+H]77 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclohex-1-ene-1-carboxamide C404.05[M+H]78 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methylthiophene-2-carboxamide C4 20.10[M+H]79 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)isoxazole-5-carboxamide C391.05[M+H]80 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)benzo[d]thiazole-2-carboxamide C457.05[M+H]81 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4,4,4-trifluorobutanamide C4 2 0.10 [M+H] 82 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)thiazole-5-carboxamide C407.05[M+H]83 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclopentanecarboxamide C394.15[M+H]84 N-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)tetrahydro-2H-pyran-4-carboxamide C408.10[M+H]85 N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide B558[M+H]86 N-(4-Methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide B538[M+H]87 N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide B552[M+H]88 N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide B559[M+H]89 N-(4-Methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide B595[M+H]90 N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide B548[M+H]91 N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide B559[M+H]92 N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide B539[M+H]93 N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide B553[M+H]94 N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide B560[M+H]95 N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide B596[M+H]96 N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide B549[M+H]97 N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide B540[M+H]98 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide B520[M+H]99 2-(3,5-Difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide B534[M+H]100 2-(3,5-difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide B541[M+H]101 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide B577[M+H]102 2-(3,5-Difluorophenyl)-N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide B530[M+H]103 N-(3-(2'-(Benzo[d]thiazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A601[M+H]104 N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide A586 [M+H] 105 N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide A824[M+H]106 N-(3-(2'-(Benzo[d]thiazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide A602 [M+H] 107 N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide A587 [M+H] 108 N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide A825[M+H]109 N-(3-(2'-(Benzo[d]thiazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide A583 [M+H] 110 2-(3,5-Difluorophenyl)-N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide A568 [M+H] 111 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3yll)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide A806[M+H]

[0330] Example Compound Structure Compound Name Synthetic Route 1 H NMR; MS[M+H]+112 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopropylureaD 1H NMR (400 MHz, DMSO-d6) δ 8.30 (s, 1H), 8.11 (s, 1H), 7.42 (d, J = 2.1 Hz, 1H), 7.25 - 7.18 (m, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.67 (s, 2H), 6.43 (s, 1H), 4.74 (d, J = 15.6 Hz, 1H), 4.56 (d, J = 15.4 Hz, 1H), 2.57 (s, 1H), 2.01 (s, 2H), 1.70 - 1.44 (m, 4H), 0.63 (dt, J = 6.3, 4.8 Hz, 2H), 0.40 (dt, J = 7.3, 4.8 Hz, 2H); 379.10 [M+1]113 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclobutylureaD 1 H NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H), 8.13 (s, 1H), 7.41 (s, 1H), 7.14 (s, 1H), 6.90 (s, 3H), 6.43 (d, J = 8.3 Hz, 1H), 4.75 (d, J = 15.3 Hz, 1H), 4.56 (d, J = 15.6 Hz, 1H), 4.10 (dd, J = 16.0, 7.8 Hz, 1H), 2.18 (td, J = 10.2, 2.3 Hz, 2H), 2.00 (s, 3H), 1.91 - 1.78 (m, 2H), 1.68 - 1.37 (m, 6H); 393.15[M+1]114 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopentylureaD 1H NMR (400 MHz, DMSO-d6) δ 8.27 (s, 1H), 8.12 (s, 1H), 7.43 (s, 1H), 7.13 (s, 1H), 6.72 (s, 3H), 6.18 (d, J = 6.9 Hz, 1H), 4.74 (d, J = 15.3 Hz, 1H), 4.55 (d, J = 15.4 Hz, 1H), 3.91 (dd, J = 13.5, 6.3 Hz, 1H), 2.00 (s, 3H), 1.87 - 1.77 (m, 2H), 1.72 - 1.45 (m, 8H), 1.40 - 1.31 (m, 2H); 407.10[M+1]115 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclopropylmethyl)urea D393.10[M+1]

[0331] Example Compound Structure Compound Name Synthetic Route 1 H NMR; MS[M+H]+116 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclohexylmethyl)urea D435.15[M+1]117 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-benzylureaD429.15[M+1]118 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-(trifluoromethoxy)phenyl)urea D499.10[M+1]119 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-cyanophenyl)urea D440.10[M+1]120 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3,4-difluorophenyl)urea D451.10[M+1]121 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(2-methoxyphenyl)ureaD 1 H NMR (400 MHz, DMSO-d6) δ 9.35 (s, 1H), 8.24 (s, 1H), 8.15 - 8.07 (m, 2H), 7.51 (s, 1H), 7.21 (s, 2H), 7.02 (dd, J = 8.1, 1.1 Hz, 1H), 6.98 - 6.92 (m, 1H), 6.91 - 6.85 (m, 1H), 6.65 (s, 2H), 4.79 (d, J = 15.2 Hz, 1H), 4.58 (d, J = 15.2 Hz, 1H), 2.03 (s, 3H), 1.65 - 1.45 (m, 4H); 445.10[M+1]122 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)ureaD 1 H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H), 8.84 (s, 1H), 8.12 (s, 1H), 8.05 (s, 1H), 7.62 - 7.44 (m, J = 6.6, 2.9, 1.2 Hz, 3H), 7.31 (d, J = 7.1 Hz, 1H), 7.28 - 7.16 (m, 2H), 6.63 (s, 2H), 4.80 (d, J = 15.0 Hz, 1H), 4.58 (d, J = 15.5 Hz, 1H), 2.08 (s, 3H), 1.66 - 1.45 (m, 4H); 483.15[M+1]123 N-(5-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-6-methylpyridin-3-yl)-3-(trifluoromotyl)benzamide E469.10[M+1]124 N-Methyl-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamidide F573[M+1]125 1-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(m-tolyl)ureaD520[M+1]126 N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide B512[M+1]127 (S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(thurifluoromethyl)benzamide B526[M+1]128 N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide B538[M+1]

[0332] Example Compound Structure Compound Name Synthetic Route 1 H NMR; MS[M+H]+129 tert-Butyl 3-((6'-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidin]-2'-yl)amino)aztidine-1-carboxylate B623[M+1]130 N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide B513[M+1]131 (S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-trifluoromethyl)nicotinamide B527[M+1]132 N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide B539[M+1]133 tert-Butyl 3-((6'-(2-methyl-5-(5-(trifluoromethyl)nicotinamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidin]-2'-yl)amino)aztidine-1-carboxylate B624[M+1]134 3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide G468[M+1]

[0333]

[0334] <Experimental Example 1> Evaluation of enzyme activity inhibition

[0335] Table 7 below shows the results of an enzyme activity inhibition experiment of kinase ACK1, BMX, and Src conducted by Reaction biology (RBC) of the United States for selected example compounds [* <10 nM: A, <100 nM: B, >100 nM: C].

[0336]

[0337]

[0338] <Experimental Example 2> Cell line inhibition assay

[0339] C4-2B and 22Rv1 cells were purchased from ATCC and cultured according to the manufacturer's instructions. 7 x 10 cells were seeded in a 96-well plate. 3 / 100 μl / well and were allowed to attach for a day. After removing the culture medium, 90 μl / well of fresh culture medium was added, and 10 μl / well of culture medium containing nine concentrations (0.076 - 500 μM) of compounds serially diluted threefold and DMSO control was added to obtain a final concentration of 0 - 50 μM, and then cultured in a CO2 incubator at 37°C for 72 hours. The degree of cell proliferation during 72 hours was measured by adding 10 μl / well of CCK-8 solution, orbitally shaking for 30 seconds, and then cultured in a CO2 incubator at 37°C for 2 hours, and measuring the absorbance at 450 nm with a microplate reader. The absorbance results of the wells to which only the culture medium and CCK-8 solution were added were subtracted from the measured absorbance results, and then the GI was calculated using GraphPad Prism 8 software. 50 was calculated.

[0340] Meanwhile, 7 x 10 in a separate 96-well plate 3 After dispensing to 100 μl / well, the cells were attached for one day and CCK-8 solution was added. The absorbance was measured and designated as the 'Growth (%) = 0' value.

[0341] The results are shown in Table 8 below [* <1 μM: A, <5 μM: B, <10 μM: C, >10 μM: D].

[0342]

[0343]

[0344] In addition, using the same method as above, experiments were conducted on A172, A549, HCI-H460, AsPC-1, MIA-Paca-2, DLD-1, HCT-116, HT-29, SW480, SW620, MDA-MB-231, and SKOV3 cell lines, and the results were as shown in Tables 9 and 10 below [* <1 μM: A, <5 μM: B, <10 μM: C, >10 μM: D].

[0345]

[0346]

[0347]

[0348] <Experimental Example 3> Measurement of kinase inhibitory activity

[0349] To measure the protein kinase inhibitory activity of the compounds of the present invention, biochemical assays were performed on a kinase panel (full kinase). The inhibitory efficacy of compounds 8 and 51 of the present invention was measured when treated with a single concentration of 1 μM, and the residual enzyme activity value was calculated. Kinases were identified when the calculated residual enzyme activity value was 40% or less, i.e., 60% or more inhibited. The results are shown in Tables 11 to 14 below.

[0350] Tables 11 and 12 below show the results for Example Compound 8.

[0351] [Correction pursuant to Rule 91, July 2024] [Table 11]

[0352] [Correction pursuant to Rule 91, July 2024] [Table 12]

[0353]

[0354] Tables 13 and 14 below show the results for Example Compound 51.

[0355] [Correction pursuant to Rule 91, July 2024] [Table 13]

[0356] [Correction pursuant to Rule 91, July 2024] [Table 14]

[0357]

[0358] Below, a formulation example of a composition containing compound 8 according to the present invention is described, but the present invention is not intended to be limited thereto, but is merely intended to be specifically described.

[0359]

[0360] <Prescription Example 1> Prescription Example of Pharmaceutical Composition

[0361] <Prescription Example 1-1> Preparation of the powder

[0362] A powder was prepared by mixing 20 mg of compound 8, 100 mg of lactose, and 10 mg of talc and filling the mixture into a sealed pouch.

[0363] <Prescription Example 1-2> Preparation of tablets

[0364] Compound 8 10 mg, corn starch 100 mg, lactose 100 mg, and magnesium stearate 2 mg were mixed and then compressed into tablets according to a conventional tablet manufacturing method.

[0365] <Prescription Example 1-3> Manufacturing of capsules

[0366] Compound 8 10 mg, corn starch 100 mg, lactose 100 mg, and magnesium stearate 2 mg were mixed, and then the above ingredients were mixed according to a conventional capsule manufacturing method and filled into a gelatin capsule to manufacture a capsule.

[0367] <Prescription Example 1-4> Preparation of injection

[0368] Compound 8 10 mg, an appropriate amount of sterile distilled water for injection, and an appropriate amount of pH adjuster were mixed, and then prepared with the above ingredient content per 1 ampoule (2 ml) according to the manufacturing method of a conventional injection.

[0369]

[0370] <Prescription Example 2> Health Supplement

[0371] <Prescription Example 2-1> Manufacturing of health food

[0372] Compound 8 1 mg, an appropriate amount of vitamin mixture (vitamin A acetate 70 μg, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 μg, vitamin C 10 mg, biotin 10 μg, nicotinamide 1.7 mg, folic acid 50 μg, calcium pantothenate 0.5 mg) and an appropriate amount of mineral mixture (ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, monobasic potassium phosphate 15 mg, dibasic calcium phosphate 55 mg, potassium citrate 90 mg, calcium carbonate 100 mg, magnesium chloride 24.8 mg) are mixed, and then granules are prepared and manufactured according to a conventional method for producing health foods. It was manufactured.

[0373] <Prescription Example 2-2> Manufacturing of a health drink

[0374] Add 1 mg of compound 8, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate, 1 g of taurine, and purified water to make a total of 900 ml, mix the above ingredients according to a conventional health drink manufacturing method, stir and heat at 85°C for about 1 hour, and then filter the resulting solution, place it in a sterilized 2 L container, seal it, sterilize it, and store it in the refrigerator.

[0375]

[0376] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A compound selected from the group consisting of a compound represented by the following chemical formula 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a precursor thereof, or a solvate thereof: [Chemical Formula 1] In the above chemical formula 1, R 1 and R 2 may be the same or different, and are hydrogen or (C1~C4) alkyl, or R 1 and R 2 They combine with each other to form a tricyclic to pentacyclic ring structure; X is selected from substituted or unsubstituted (C1~C4)alkyl, (C3~C6)cycloalkyl, (C4~C6)cycloalkenyl, phenyl, benzyl, or a 5- or 6-ring single or double heterocyclic compound, wherein said substitution is (C1~C4)alkyl, (C1~C4)alkoxy, (C3~C6)cycloalkyl, trifluoromethyl, trifluoromethyl(C1~C2)alkoxy, halo, hydroxy, imidazolyl, (C1~C2)alkylimidazolyl, (C1~C2)alkoxyphenyl, morpholino, cyano, oxo(=O), (C1~C2)alkoxy(C1~C2)alkyl(C1~C2)alkylamino, piperazinyl, (C1~C2)alkylpiperazinyl, At least one selected from the group consisting of ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, A is selected from morpholino or -NH-Y, wherein Y is selected from hydrogen, substituted or unsubstituted phenyl, benzyl, (C1~C4)alkyl, (C2~C3)alkenyl, (C3~C6)cycloalkyl, pyridinyl, pyrazolyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, or aztidine, wherein the substitution is (C1~C2)alkyl, (C1~C4)alkoxy, piperazinyl, (C1~C2)alkylpiperazinyl, acetylpiperazinyl, morpholino, morpholine-4-carbonyl, (C1~C2)alkylpiperazin-1-carbonyl, oxetanyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl, imidazolyl, pyrrolidinyl, di(C1~C2)alkylaminopyrrolidinyl, piperidinyl, At least one selected from the group consisting of acetylpiperidinyl, di(C1~C2)alkylaminopiperidinyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl, halo, trifluoro(C1~C2)alkyl, trifluoro(C1~C2)alkoxy, di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, pyridinyl, furanyl, hydroxy and tert-butoxy carbonyl (BOC); Z is CH or N; L is CH2 or NH; n1 or n2 is an integer between 0 and 1.

2. In claim 1, The compound is characterized in that the compound is a compound represented by chemical formula 1-1: [Chemical Formula 1-1] In the above chemical formula 1-1, X is selected from substituted or unsubstituted (C1~C4)alkyl, (C3~C6)cycloalkyl, (C4~C6)cycloalkenyl, phenyl, benzyl, or a 5- or 6-ring single or double heterocyclic compound, wherein said substitution is (C1~C4)alkyl, (C1~C4)alkoxy, (C3~C6)cycloalkyl, trifluoromethyl, trifluoromethyl(C1~C2)alkoxy, halo, hydroxy, imidazolyl, (C1~C2)alkylimidazolyl, (C1~C2)alkoxyphenyl, morpholino, cyano, oxo(=O), (C1~C2)alkoxy(C1~C2)alkyl(C1~C2)alkylamino, piperazinyl, (C1~C2)alkylpiperazinyl, At least one selected from the group consisting of ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino; A is selected from morpholino or -NH-Y, wherein Y is selected from hydrogen, substituted or unsubstituted phenyl, benzyl, (C1~C4)alkyl, (C2~C3)alkenyl, (C3~C6)cycloalkyl, pyridinyl, pyrazolyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, or aztidine, wherein the substitution is (C1~C2)alkyl, (C1~C4)alkoxy, piperazinyl, (C1~C2)alkylpiperazinyl, acetylpiperazinyl, morpholino, morpholine-4-carbonyl, (C1~C2)alkylpiperazin-1-carbonyl, oxetanyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl, imidazolyl, pyrrolidinyl, di(C1~C2)alkylaminopyrrolidinyl, piperidinyl, At least one selected from the group consisting of acetylpiperidinyl, di(C1~C2)alkylaminopiperidinyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl, halo, trifluoro(C1~C2)alkyl, trifluoro(C1~C2)alkoxy, di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, pyridinyl, furanyl, hydroxy and tert-butoxy carbonyl (BOC); Z is CH or N; L is CH2 or NH; n is an integer between 0 and 1.

3. In claim 1, A compound characterized in that the above 5- or 6-ring single or double heterocyclic compound is selected from the group consisting of thiophene, furan, pyrazole, oxazole, thiazole, pyridine, pyran, tetrahydropyran, oxazine, thiazine, pyrimidine, piperazine, and benzothiazole.

4. In claim 1, The compound is characterized in that the compound is a compound represented by chemical formula 1-2: [Chemical Formula 1-2] In the above chemical formula 1-2, R 3 Inland R 5 are each the same or different and are selected from the group consisting of hydrogen, (C1~C2)alkyl, (C1~C2)alkoxy, trifluoromethyl, halo, hydroxy, (C1~C2)alkylimidazolyl, (C1~C2)alkoxyphenyl, morpholino, (C1~C2)alkoxy(C1~C2)alkyl(C1~C2)alkylamino, piperazinyl, (C1~C2)alkylpiperazinyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino, A 1 is morpholino or -NH-Y 1 Selected from, Above Y 1 is selected from hydrogen, (C3~C4)cycloalkyl, benzyl, 1H-pyrazolyl, di(C1~C2)alkyl1H-pyrazolyl, (oxetan-3-yl)-1H-pyrazolyl, trifluoro(C1~C2)alkyl-1H-pyrazolyl, pyridinyl(C1~C2)alkyl, hydroxy(C1~C2)alkyl, hydroxy(C2-C4)alkenyl, hydroxy(C3-C6)cycloalkyl, monopolyno(C3~C4)alkyl, furanyl(C1~C2)alkyl, tert-butoxy carbonyl (BOC) substituted aztidine, tetrahydropyranyl, benzothiazolyl, benzofuranyl or substituted or unsubstituted phenyl or pyridinyl, wherein said substitution is (C1~C2)alkyl, At least one selected from the group consisting of (C1~C2)alkoxy, halo, trifluoro(C1~C2)alkoxy, piperazinyl, (C1~C2)alkylpiperazinyl, acetylpiperazinyl, morpholino, morpholine-4-carbonyl, (C1~C2)alkylpiperazin-1-carbonyl, ((C1~C2)alkylpiperazin-1-yl)(C1~C2)alkyl, imidazolyl, di(C1~C2)alkylaminopyrrolidinyl, piperidinyl, acetylpiperidinyl, di(C1~C2)alkylaminopiperidinyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl and di(C1~C2)alkylamino(C1~C2)alkyl(C1~C2)alkylamino).

5. In claim 1, The compound is characterized in that the compound is a compound represented by chemical formula 1-3: [Chemical Formula 1-3] In the above chemical formula 1-3, X 1 is selected from (C3~C6)cycloalkyl, oxo(C3~C6)cycloalkyl, (C4~C6)cycloalkenyl, thiophene, (C1~C2)alkylthiophene, furan, thiazole, oxazole, benzothiazole, tetrahydropyran, trifluoro(C1~C3)alkyl; or pyridinyl substituted with a substituent selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy, trifluoromethyl, halo and hydroxy; A 2 is morpholino or -NH-Y 2 Selected from, Above Y 2 is at least one selected from the group consisting of hydrogen, benzyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, (C1~C2)alkylpyridinyl, pyridinyl(C1~C2)alkyl, hydroxy(C1~C2)alkyl, hydroxy(C2-C4)alkenyl, hydroxy(C3-C6)cycloalkyl, monopolyno(C3~C4)alkyl, furanyl(C1~C2)alkyl, ((C1~C2)alkylpiperazin-1-yl)piperidinyl-trifluoro(C1~C2)alkoxypyridinyl, and tert-butoxy carbonyl (BOC) substituted aztidine.

6. In claim 1, The compound is characterized in that the compound is a compound represented by the chemical formula 1-4: [Chemical Formula 1-4] In the above chemical formula 1-4, X 2 is selected from (C3~C6)cycloalkyl, (C3~C6)cycloalkyl(C1~C2)alkyl, benzyl, or substituted or unsubstituted phenyl, wherein the substitution is at least one selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy, halo, trifluoro(C1~C2)alkyl, trifluoro(C1~C2)alkoxy and cyano, A 3 is morpholino or -NH-Y 3 Selected from, Above Y 3 is at least one selected from hydrogen or (C1~C2)alkylpyridinyl.

7. In claim 1, The compound is characterized in that the compound is a compound represented by chemical formula 1-5: [Chemical Formula 1-5] In the above chemical formula 1-5, X 3 is selected from substituted or unsubstituted phenyl, wherein the substitution is at least one selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy and halo, A 4 is morpholino or -NH-Y 4 Selected from, Above Y 4 is at least one selected from hydrogen, benzyl, tetrahydropyranyl, benzothiazolyl, benzofuranyl, monopolyno(C3~C4)alkyl, furanyl(C1~C2)alkyl or pyridinyl(C1~C2)alkyl.

8. In claim 1, The compound is characterized in that the compound is a compound represented by the chemical formula 1-6: [Chemical Formula 1-6] In the above chemical formula 1-6, X 4 is selected from substituted or unsubstituted phenyl, wherein the substitution is at least one selected from the group consisting of (C1~C2)alkyl, (C1~C2)alkoxy, halo and trifluoromethyl, A 5 is morpholino or -NH-Y 5 Selected from, Above Y 5 is hydrogen, or at least one selected from (C1~C2)alkylpyridinyl.

9. In claim 1, The above compounds are N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 1), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 2), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 3), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-fluoro-3-(trifluoromethyl)benzamide (Compound 4), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido]pyrimidine)-yl4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide (Compound 5), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide (Compound 6), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide (Compound 7), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide (Compound 8), N-(3-(2'-amino-7'-oxo-5'-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,4-difluorobenzamide (Compound 9),N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,4-difluorobenzamide (Compound 10), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide (Compound 11), N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (Compound 12), 3-bromo-N-(3-(2'-(cyclopropylamine)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)benzamide (Compound 13), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2,4-difluorobenzamide (Compound 14), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3,5-difluorobenzamide (Compound 15), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxybenzamide (Compound 16), N-(3-(2'amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H-yl)-4-methylphenyl)-3-chloro-2-fluoro-5-(trifluoromethyl)benzamide (Compound 17), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-fluoro-5-(trifluoromethyl)benzamide (Compound 18),N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-methoxy-5-(trifluoromethyl)benzamide (Compound 19), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4'-methoxy-5-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxyamide (Compound 20), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-6-(trifluoromethyl)picolinamide (Compound 21), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (Compound 22), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-hydroxy-5-(trifluoromethyl)benzamide (Compound 23), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 24), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-chloro-5-(trifluoromethyl)benzamide (Compound 25), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-chloro-5-(trifluoromethyl)benzamide (Compound 26), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide (Compound 27),N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide (Compound 28), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-morpholino-5-(trifluoromethyl)benzamide (Compound 29), N-(3-(2'-(cycloamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide (Compound 30), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-methoxyethyl)(methyl)amino)-5-(trifluoromethyl)benzamide (Compound 31), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 32), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 33), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 34), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(piperazin-1-yl)-5-(trifluoromethyl)benzamide (Compound 35),N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyl)(methyl)amino)-5-(trifluoromethyl)benzamide (Compound 36), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-((2-(dimethylamino)ethyl)(methylamino)-5-(trifluoromethyl)benzamide (Compound 37), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 38), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 39), N-(4-methyl-3-(2'-((4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 40), N-(4-methyl-3-(2'-((4-(4-methylpiperazine-1-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 41), N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 42), N-(4-methyl-3-(2'-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 43),N-(3-(2'-((4-(1H-imidazol-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 44), N-(4-methyl-3-(7'-oxo-2'-((4-(piperazin-1-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 45), (S)-N-(3-(2'-((4-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 46), N-(4-methyl-3-(7'-oxo-2'-((4-(piperidin-4-yl)phenyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 47), N-(4-methyl-3-(2'-((3-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 48), N-(3-(2'-((4-(1-acetylpiperidin-4-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 49), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (Compound 50), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 51), N-(4-methyl-3-(2'-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 52), N-(3-(2'-((2-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 53), N-(3-(2'-((2-methoxy-4-(morpholine-4-carbonyl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 54), N-(3-(2'-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 55), N-(3-(2'-((3-methoxy-4-morpholinophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 56), N-(3-(2'-((4-(4-ethylpiperazin-1-yl)-3-fluorophenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 57), N-(3-(2'-((6-(4-ethylpiperazin-1-yl)-2-methoxypyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 58), N-(4-methyl-3-(7'-oxo-2'-(phenylamino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 59), N-(3-(2'-((4-(4-(dimethylaminopiperidin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 60), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (Compound 61), N-(3-(2'-(cyclopropylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide (Compound 62), N-(3-(2'-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 63), N-(4-methyl-3-(7'-oxo-2'-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 64), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide (Compound 65), N-(3-(2'-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 66),N-(3-(2'-((3-methoxy-4-(piperazin-1-yl)phenyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 67), N-(3-(2'-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 68), N-(3-(2'-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 69), N-(3-(2'-((2-hydroxy)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 70), 1-(4-Fluorophenyl)-3-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)urea (Compound 71), 4-chloro-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)benzamide (Compound 72), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)thiophene-2-carboxamide (Compound 73), N-(4-Methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)furan-2-carboxamide (Compound 74), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclobutanecarboxamide (Compound 75), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-oxocyclobutane-1-carboxamide (Compound 76), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclohex-1-ene-1-carboxamide (Compound 77), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4-methylthiophene-2-carboxamide](Compound 78), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)isoxazole-5-carboxamide (Compound 79), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)benzo[d]thiazole-2-carboxamide (Compound 80), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-4,4,4-trifluorobutanamide (Compound 81), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)thiazole-5-carboxamide (Compound 82), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)cyclopentanecarboxamide (Compound 83), N-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)tetrahydro-2H-pyran-4-carboxamide (Compound 84),N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 85), N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 86), N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 87), N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 88), N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 89), N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 90), N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 91), N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 92), N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 93), N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 94), N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 95), N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 96), N-(3-(2'-(Benzylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide (Compound 97), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-morpholino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 98), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((tetrahydro-2H-pyran-4-yl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 99), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(7'-oxo-2'-((pyridin-3-ylmethyl)amino)-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 100), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((3-morpholinopropyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 101), 2-(3,5-difluorophenyl)-N-(3-(2'-((furan-2-ylmethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide (Compound 102), N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 103), N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 104), N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Compound 105), N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 106), N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 107), N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-5-(trifluoromethyl)nicotinamide (Compound 108),N-(3-(2'-(Benzo[d]cyanazol-5-ylamino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-2-(3,5-difluorophenyl)acetamide (Compound 109), 2-(3,5-difluorophenyl)-N-(3-(2'-((2,3-dihydrobenzofuran-4-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)acetamide (Compound 110), 2-(3,5-difluorophenyl)-N-(4-methyl-3-(2'-((6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin-3yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)acetamide (Compound 111), 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopropylurea (Compound 112), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclobutyl urea (Compound 113), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-cyclopentyl urea (Compound 114), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclopropylmethyl)urea (Compound 115), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclohexylmethyl)urea (Compound 116), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(cyclohexylmethyl)urea (Compound 116).3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-benzylurea (Compound 117), 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(4-(trafluoromethoxy)phenyl)urea (Compound 118), 1-(3-(2'-amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-cyanophenyl)urea (Compound 119), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3,4-difluorophenyl)urea (Compound 120), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(2-methoxyphenyl)urea (Compound 121), 1-(3-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea (Compound 122), N-(5-(2'-Amino-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-6-methylpyridin-3-yl)-3-(trifluoromotyl)benzamide (Compound 123), N-Methyl-N-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(trifluoromethyl)benzamidide (Compound 124), 1-(4-methyl-3-(2'-((6-methylpyridin-3-yl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)phenyl)-3-(m-tolyl)urea (Compound 125), N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 126), (S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 127), N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropane-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (Compound 128), tert-butyl 3-((6'-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-2'-yl)amino)aztidine-1-carboxylate (Compound 129), N-(3-(2'-((2-hydroxyethyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 130), (S)-N-(3-(2'-((1-hydroxypropen-2-yl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 131), N-(3-(2'-(((1r,3r)-3-hydroxycyclobutyl)amino)-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (Compound 132), tert-butyl 3-((6'-(2-methyl-5-(5-(trifluoromethyl)nicotinamido)phenyl)-7'-oxo-6',7'-dihydro-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-2'-yl)amino)aztidine-1-carboxylate (Compound 133),and a compound characterized by being selected from the group consisting of 3-(2'-amino-7'-oxo-5'H-spiro[cyclopropene-1,8'-pyrido[4,3-d]pyrimidine]-6'(7'H)-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (Compound 134).

10. In claim 1, The above compounds are ABL1, ABL2 / ARG, ACK1, ARAF, BLK, BMX / ETK, BRAF, BRK, BTK, C-KIT, C-SRC, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5. EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GLK / MAP4K3, HCK, HGK / MAP4K4, HIPK4, HPK1 / MAP4K1, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS2, LCK, LIMK1, LIMK2, LOK / STK10, LRRK2, LYN, LYN B, MEK5, MEKK2, MEKK3, MINK / MINK1, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, NEK4, P38A / MAPK14, P38B / MAPK11, PDGFRA, PDGFRB, PKAcg, PYK2, RAF1, RET, RIPK3, ROS / ROS1, RSK1, SIK1, SIK2, SIK3, SLK / STK2, SRMS, STK32B / YANK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TEC, TESK2, TIE2 / TEK, TNIK, TNK1, TRKA, TRKB, TRKC, TXK, A compound characterized by inhibiting one or more protein kinases selected from the group consisting of TYK1 / LTK, TYK2, TYRO3 / SKY, YES / YES1, YSK4 / MAP3K19 and ZAK / MLTK.

11. A pharmaceutical composition for treating or preventing a protein kinase-related disease, comprising a compound according to claim 1.

12. In claim 11, The above protein kinases are ABL1, ABL2 / ARG, ACK1, ARAF, BLK, BMX / ETK, BRAF, BRK, BTK, C-KIT, C-SRC, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5. EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GLK / MAP4K3, HCK, HGK / MAP4K4, HIPK4, HPK1 / MAP4K1, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS2, LCK, LIMK1, LIMK2, LOK / STK10, LRRK2, LYN, LYN B, MEK5, MEKK2, MEKK3, MINK / MINK1, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, NEK4, P38A / MAPK14, P38B / MAPK11, PDGFRA, PDGFRB, PKAcg, PYK2, RAF1, RET, RIPK3, ROS / ROS1, RSK1, SIK1, SIK2, SIK3, SLK / STK2, SRMS, STK32B / YANK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TEC, TESK2, TIE2 / TEK, TNIK, TNK1, TRKA, TRKB, TRKC, TXK, A pharmaceutical composition characterized in that it is at least one protein kinase selected from the group consisting of TYK1 / LTK, TYK2, TYRO3 / SKY, YES / YES1, YSK4 / MAP3K19 and ZAK / MLTK.

13. In claim 11, A pharmaceutical composition characterized in that the above protein kinase-related disease is cancer.

14. In claim 13, A pharmaceutical composition characterized in that the cancer disease is selected from the group consisting of prostate cancer, endometrial cancer, bladder cancer, stomach cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenoma, head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, urethral cancer, leukemia, multiple myeloma, blood cancer, lymphoma, and fibroadenoma.

15. In claim 13, A pharmaceutical composition characterized in that the above pharmaceutical composition is administered in combination therapy with one or more anticancer agents selected from the group consisting of cytotoxic anticancer agents, targeted anticancer agents, immunotherapy agents, and metabolism-modulating anticancer agents.

16. In claim 11, A pharmaceutical composition characterized in that the compound has an inhibitory effect of 60% or more when treated with a single concentration of 1 μM of the compound against protein kinase.

17. A health functional food for improving or preventing a protein kinase-related disease, comprising a compound according to claim 1.

18. In claim 17, The above protein kinases are ABL1, ABL2 / ARG, ACK1, ARAF, BLK, BMX / ETK, BRAF, BRK, BTK, C-KIT, C-SRC, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5. EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GLK / MAP4K3, HCK, HGK / MAP4K4, HIPK4, HPK1 / MAP4K1, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS2, LCK, LIMK1, LIMK2, LOK / STK10, LRRK2, LYN, LYN B, MEK5, MEKK2, MEKK3, MINK / MINK1, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, NEK4, P38A / MAPK14, P38B / MAPK11, PDGFRA, PDGFRB, PKAcg, PYK2, RAF1, RET, RIPK3, ROS / ROS1, RSK1, SIK1, SIK2, SIK3, SLK / STK2, SRMS, STK32B / YANK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TEC, TESK2, TIE2 / TEK, TNIK, TNK1, TRKA, TRKB, TRKC, TXK, A health functional food characterized by being at least one protein kinase selected from the group consisting of TYK1 / LTK, TYK2, TYRO3 / SKY, YES / YES1, YSK4 / MAP3K19, and ZAK / MLTK.

19. In claim 17, A health functional food characterized in that the above protein kinase-related disease is cancer.

Citation Information

Patent Citations

  • Bicyclic heterocycles as FGFR4 inhibitors

    KR1020170123634A

  • Oxidation and corrosion prevention in semiconductor devices and semiconductor device assemblies

    KR1020220141761A

  • Heteroaryl compounds and uses thereof

    US20140296233A1

  • Inhibitors of the fibroblast growth factor receptor

    WO2014011900A2

  • Heterobicyclic compounds and their use as FGFR4 receptor inhibitors

    WO2015108992A1